

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/165, 31/40, 31/295, 31/135		A2	(11) International Publication Number: WO 95/21612 (43) International Publication Date: 17 August 1995 (17.08.95)
<p>(21) International Application Number: PCT/US94/12293</p> <p>(22) International Filing Date: 26 October 1994 (26.10.94)</p> <p>(30) Priority Data: 08/194,210 8 February 1994 (08.02.94) US 08/288,668 9 August 1994 (09.08.94) US </p> <p>(60) Parent Applications or Grants (63) Related by Continuation US 08/014,813 (CIP) Filed on 8 February 1993 (08.02.93) US 08/194,210 (CIP) Filed on 8 February 1994 (08.02.94) US 08/288,668 (CIP) Filed on 9 August 1994 (09.08.94) </p> <p>(71) Applicant (for all designated States except US): NPS PHARMACEUTICALS, INC. [US/US]; 420 Chipeta Way, Salt Lake City, UT 84108 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MUELLER, Alan, L. [US/US]; 1363 East Thornton Avenue, Salt Lake City, UT 84105 (US). VAN WAGENEN, Bradford, C. [US/US];</p>		<p>3969 South 3250 East, Salt Lake City, UT 84124 (US). DELMAR, Eric, G. [US/US]; 2967 East St. Mary's Circle, Salt Lake City, UT 84108 (US). BALANDRIN, Manuel, F. [US/US]; 9184 South Wren Drive, Sandy, UT 84093 (US). MOE, Scott, T. [US/US]; 6152 South Vinefield Drive, Salt Lake City, UT 84105 (US). ARTMAN, Linda, D. [US/US]; 1363 East Thornton Avenue, Salt Lake City, UT 84105 (US).</p> <p>(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90017-2066 (US).</p> <p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES</p> <p>(57) Abstract</p> <p>Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compounds is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SI	Slovenia
CH	Switzerland	KZ	Kazakhstan	SK	Slovakia
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	TD	Chad
CN	China	LU	Luxembourg	TG	Togo
CS	Czechoslovakia	LV	Latvia	TJ	Tajikistan
CZ	Czech Republic	MC	Monaco	TT	Trinidad and Tobago
DE	Germany	MD	Republic of Moldova	UA	Ukraine
DK	Denmark	MG	Madagascar	US	United States of America
ES	Spain	ML	Mali	UZ	Uzbekistan
FI	Finland	MN	Mongolia	VN	Viet Nam
FR	France				
GA	Gabon				

WO 95/21612

PCT/US94/12293

1

DESCRIPTIONCompounds Active at a Novel Site on Receptor-Operated Calcium Channels Useful for Treatment of Neurological Disorders and DiseasesField of the Invention

This invention relates to compounds useful as neuro-protectants, anticonvulsants, anxiolytics, analgesics, muscle relaxants or adjuvants to general anesthetics. The 5 invention relates as well to methods useful for treatment of neurological disorders and diseases, including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage such as in cardiac arrest or neonatal 10 distress, epilepsy, anxiety, and neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease and Parkinson's Disease. The invention relates as well to methods of screening for compounds active at a novel site on receptor-operated calcium channels, and thereby 15 possessing therapeutic utility as neuroprotectants, anti-convulsants, anxiolytics, analgesics, muscle relaxants or adjuvants to general anesthetics, and/or possessing potential therapeutic utility for the treatment of neurological disorders and diseases as described above.

20 Background of the Invention

The following is a description of relevant art, none of which is admitted to be prior art to the claims.

Glutamate is the major excitatory neurotransmitter in the mammalian brain. Glutamate binds or interacts with 25 one or more glutamate receptors which can be differentiated pharmacologically into several subtypes. In the mammalian central nervous system (CNS) there are three main subtypes of ionotropic glutamate receptors, defined pharmacologically by the selective agonists N-methyl-D-30 aspartate (NMDA), kainate (KA), and α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA). The NMDA receptor has been implicated in a variety of neurological

WO 95/21612

PCT/US94/12293

pathologies including stroke, head trauma, spinal cord injury, epilepsy, anxiety, and neurodegenerative diseases such as Alzheimer's Disease (Watkins and Collingridge, *The NMDA Receptor*, Oxford: IRL Press, 1989). A role for NMDA receptors in nociception and analgesia has been postulated as well (Dickenson, *A cure for wind-up: NMDA receptor antagonists as potential analgesics*. *Trends Pharmacol. Sci.* 11: 307, 1990). More recently, AMPA receptors have been widely studied for their possible contributions to such neurological pathologies (Fisher and Bogousslavsky, *Evolving toward effective therapy for acute ischemic stroke*. *J. Amer. Med. Assoc.* 270: 360, 1993; Yamaguchi et al., *Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models*. *Epilepsy Res.* 15: 179, 1993).

When activated by glutamate, the endogenous neurotransmitter, the NMDA receptor permits the influx of extracellular calcium (Ca^{2+}) and sodium (Na^+) through an associated ion channel. The NMDA receptor allows considerably more influx of Ca^{2+} than do kainate or AMPA receptors (but see below), and is an example of a receptor-operated Ca^{2+} channel. Normally, the channel is opened only briefly, allowing a localized and transient increase in the concentration of intracellular Ca^{2+} ($[\text{Ca}^{2+}]_i$) which, in turn, alters the functional activity of the cell. However, prolonged increases in $[\text{Ca}^{2+}]_i$, resulting from chronic stimulation of the NMDA receptor, are toxic to the cell and lead to cell death. The chronic elevation in $[\text{Ca}^{2+}]_i$, resulting from stimulation of NMDA receptors, is said to be a primary cause of neuronal degeneration following a stroke (Choi, *Glutamate neurotoxicity and diseases of the nervous system*. *Neuron* 1: 623, 1988). Overstimulation of NMDA receptors is also said to be involved in the pathogenesis of some forms of epilepsy (Dingledine et al., *Excitatory amino acid receptors in epilepsy*. *Trends Pharmacol. Sci.* 11: 334,

WO 95/21612

PCT/US94/12293

1990), anxiety (Wiley and Balster, Preclinical evaluation of N-methyl-D-aspartate antagonists for antianxiety effects: A review. In: *Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?* NPP Books, Ann Arbor, Michigan, pp. 801-815, 1992) neurodegenerative diseases (Meldrum and Garthwaite, Excitatory amino acid neurotoxicity and neurodegenerative disease. *Trends Pharmacol. Sci.* 11: 379, 1990), and hyperalgesic states (Dickenson, A cure for wind-up: NMDA receptor antagonists as potential analgesics. *Trends Pharmacol. Sci.* 11: 307, 1990).

The activity of the NMDA receptor-ionophore complex is regulated by a variety of modulatory sites that can be targeted by selective antagonists. Competitive antagonists, such as the phosphonate AP5, act at the glutamate binding site, whereas noncompetitive antagonists, such as phencyclidine (PCP), MK-801 or magnesium (Mg^{2+}), act within the associated ion channel (ionophore). There is also a glycine binding site that can be blocked selectively with compounds such as 7-chlorokynurenic acid. There is evidence suggesting that glycine acts as a co-agonist, so that both glutamate and glycine are necessary to fully elicit NMDA receptor-mediated responses. Other potential sites for modulation of NMDA receptor function include a zinc (Zn^{2+}) binding site and a sigma ligand binding site. Additionally, endogenous polyamines such as spermine are believed to bind to a specific site and so potentiate NMDA receptor function (Ransom and Stec, Cooperative modulation of [3H]MK-801 binding to the NMDA receptor-ion channel complex by glutamate, glycine and polyamines. *J. Neurochem.* 51: 830, 1988). The potentiating effect of polyamines on NMDA receptor function may be mediated via a specific receptor site for polyamines; polyamines demonstrating agonist, antagonist, and inverse agonist activity have been described (Reynolds, Arcaine is a competitive antagonist of the polyamine site on the NMDA receptor. *Europ. J. Pharmacol.* 177: 215, 1990; Williams

WO 95/21612

PCT/US94/12293

4

et al., Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. *Neuron* 5: 199, 1990). Radioligand binding studies have demonstrated 5 additionally that higher concentrations of polyamines inhibit NMDA receptor function (Reynolds and Miller, Ifenprodil is a novel type of NMDA receptor antagonist: Interaction with polyamines. *Molec. Pharmacol.* 36: 758, 1989; Williams et al., Effects of polyamines on the 10 binding of [³H]MK-801 to the NMDA receptor: Pharmacological evidence for the existence of a polyamine recognition site. *Molec. Pharmacol.* 36: 575, 1989; Sacaan and Johnson, Characterization of the stimulatory and inhibitory effects of polyamines on [³H]TCP binding to the NMDA 15 receptor-ionophore complex. *Molec. Pharmacol.* 37: 572, 1990). This inhibitory effect of polyamines on NMDA receptors is probably a nonspecific effect (i.e., not mediated via the polyamine receptor) because patch clamp electro-physiological studies have demonstrated that this 20 inhibition is produced by compounds previously shown to act at the polyamine receptor as either agonists or antagonists (Donevan et al., Arcaine Blocks N-Methyl-D-Aspartate Receptor Responses by an Open Channel Mechanism: Whole-Cell and Single-Channel Recording Studies in 25 Cultured Hippocampal Neurons. *Molec. Pharmacol.* 41: 727, 1992; Rock and Macdonald, Spermine and Related Polyamines Produce a Voltage-Dependent Reduction of NMDA Receptor Single-Channel Conductance. *Molec. Pharmacol.* 42: 157, 1992).

30 Recent studies have demonstrated the molecular diversity of glutamate receptors (reviewed by Nakanishi, Molecular Diversity of Glutamate Receptors and Implications for Brain Function. *Science* 258: 597, 1992). At least five distinct NMDA receptor subunits (NMDAR1 and 35 NMDAR2A through NMDAR2D), each encoded by a distinct gene, have been identified to date. Also, in NMDAR1, alternative splicing gives rise to at least six additional

WO 95/21612

PCT/US94/12293

isoforms. It appears that NMDAR1 is a necessary subunit, and that combination of NMDAR1 with different members of NMDAR2 forms the fully functional NMDA receptor-ionophore complex. The NMDA receptor-ionophore complex, thus, can 5 be defined as a hetero-oligomeric structure composed of at least NMDAR1 and NMDAR2 subunits; the existence of additional, as yet undiscovered, subunits is not excluded by this definition. NMDAR1 has been shown to possess binding sites for glutamate, glycine, Mg²⁺, MK-801, and Zn²⁺. The 10 binding sites for sigma ligands and polyamines have not yet been localized on NMDA receptor subunits, although ifenprodil recently has been reported to be more potent at the NMDAR2B subunit than at the NMDAR2A subunit (Williams, Ifenprodil discriminates subtypes of the N-Methyl-D- 15 aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44: 851, 1993).

Several distinct subtypes of AMPA and kainate receptors have been cloned as well (reviewed by Nakanishi, 20 Molecular diversity of glutamate receptors and implications for brain function. Science 258: 597, 1992). Of particular relevance are the AMPA receptors designated GluR1, GluR2, GluR3, and GluR4 (also termed GluRA through GluRD), each of which exists in one of two forms, termed 25 flip and flop, which arise by RNA alternative splicing. GluR1, GluR3 and GluR4, when expressed as homomeric or heteromeric receptors, are permeable to Ca²⁺, and are therefore examples of receptor-operated Ca²⁺ channels. Expression of GluR2 alone or in combination with the other 30 subunits gives rise to a receptor which is largely impermeable to Ca²⁺. As most native AMPA receptors studied *in situ* are not Ca²⁺-permeable (discussed above), it is believed that such receptors *in situ* possess at least one GluR2 subunit. Furthermore, it is hypothesized that the 35 GluR2 subunit is functionally distinct by virtue of the fact that it contains an arginine residue within the putative pore-forming transmembrane region II; GluR1,

WO 95/21612

PCT/US94/12293

GluR3 and GluR4 all contain a glutamine residue in this critical region (termed the Q/R site, where Q and R are the single letter designations for glutamine and arginine, respectively). The activity of the AMPA receptor is regulated by a number of modulatory sites that can be targeted by selective antagonists (Honore et al., Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. *Science* 241: 701, 1988; Donevan and Rogawski, GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. *Neuron* 10: 51, 1993). Competitive antagonists such as NBQX act at the glutamate binding site, whereas compounds such as GYKI 52466 appear to act noncompetitively at an associated allosteric site.

Compounds that act as competitive or noncompetitive antagonists at the NMDA receptor are said to be effective in preventing neuronal cell death in various *in vitro* neurotoxicity assays (Meldrum and Garthwaite, Excitatory amino acid neurotoxicity and neurodegenerative disease. *Trends Pharmacol. Sci.* 11: 379, 1990) and in *in vivo* models of stroke (Scatton, Therapeutic potential of NMDA receptor antagonists in ischemic cerebrovascular disease in *Drug Strategies in the Prevention and Treatment of Stroke*, IBC Technical Services Ltd., 1990). Such compounds are also effective anticonvulsants (Meldrum, Excitatory amino acid neurotransmission in epilepsy and anticonvulsant therapy in *Excitatory Amino Acids*. Meldrum, Moroni, Simon, and Woods (Eds.), New York: Raven Press, p. 655, 1991), anxiolytics (Wiley and Balster, Preclinical evaluation of N-methyl-D-aspartate antagonists for anti-anxiety effects: A review. In: *Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?* NPP Books, Ann Arbor, Michigan, pp. 801-815, 1992), and analgesics (Dickenson, A cure for wind-up: NMDA receptor antagonists as potential analgesics. *Trends Pharmacol. Sci.* 11: 307, 1990), and certain NMDA receptor antagonists may lessen dementia associated with

WO 95/21612

PCT/US94/12293

Alzheimer's Disease (Hughes, Merz' novel approach to the treatment of dementia. *Script No. 1666: 24, 1991*).

Similarly, AMPA receptor antagonists have come under intense scrutiny as potential therapeutic agents for the treatment of such neurological disorders and diseases. AMPA receptor antagonists have been shown to possess neuroprotectant (Fisher and Bogousslavsky, Evolving toward effective therapy for acute ischemic stroke. *J. Amer. Med. Assoc.* 270: 360, 1993) and anticonvulsant (Yamaguchi et al., Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. *Epilepsy Res.* 15: 179, 1993) activity in animal models of ischemic stroke and epilepsy, respectively.

The nicotinic cholinergic receptor present in the mammalian CNS is another example of a receptor-operated Ca^{2+} channel (Deneris et al., Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. *Trends Pharmacol. Sci.* 12: 34, 1991). Several distinct receptor subunits have been cloned, and these subunits can be expressed, in *Xenopus* oocytes for example, to form functional receptors with their associated cation channels. It is hypothesized that such receptor-ionophore complexes are heteropentameric structures. The possible role of nicotinic receptor-operated Ca^{2+} channels in the pathology of neurological disorders and diseases such as ischemic stroke, epilepsy and neurodegenerative diseases has been largely unexplored.

It has been demonstrated previously (for reviews see Jackson and Usherwood, Spider toxins as tools for dissecting elements of excitatory amino acid transmission. *Trends Neurosci.* 11: 278, 1988; Jackson and Parks, Spider Toxins: Recent Applications In Neurobiology. *Annu. Rev. Neurosci.* 12: 405, 1989; Saccomano et al., Polyamine spider toxins: Unique pharmacological tools. *Annu. Rep. Med. Chem.* 24: 287, 1989; Usherwood and Blagbrough, Spider Toxins Affecting Glutamate Receptors: Polyamines in

WO 95/21612

PCT/US94/12293

Therapeutic Neurochemistry. *Pharmacol. Therap.* 52: 245, 1991; Kawai, Neuroactive Toxins of Spider Venoms. *J. Toxicol. Toxin Rev.* 10: 131, 1991) that certain spider and wasp venoms contain arylalkylamine toxins (also called 5 polyamine toxins, arylamine toxins, acylpolyamine toxins or polyamine amide toxins) with activity against glutamate receptors in the mammalian CNS. Arylalkylamine toxins were initially reported to be selective antagonists of the AMPA/kainate subtypes of glutamate receptors in the 10 mammalian CNS (Kawai et al., Effect of a spider toxin on glutaminergic synapses in the mammalian brain. *Biomed. Res.* 3: 353, 1982; Saito et al., Spider Toxin (JSTX) blocks glutamate synapse in hippocampal pyramidal neurons. *Brain Res.* 346: 397, 1985; Saito et al., Effects of a 15 spider toxin (JSTX) on hippocampal CA1 neurons *in vitro*. *Brain Res.* 481: 16, 1989; Akaike et al., Spider toxin blocks excitatory amino acid responses in isolated hippocampal pyramidal neurons. *Neurosci. Lett.* 79: 326, 1987; Ashe et al., Argiotoxin-636 blocks excitatory 20 synaptic transmission in rat hippocampal CA1 pyramidal neurons. *Brain Res.* 480: 234, 1989; Jones et al., Philanthotoxin blocks quisqualate-induced, AMPA-induced and kainate-induced, but not NMDA-induced excitation of rat brainstem neurones *in vivo*. *Br. J. Pharmacol.* 101: 25 968, 1990). Subsequent studies have demonstrated that while certain arylalkylamine toxins are both nonpotent and nonselective at various glutamate receptors, other arylalkylamines are both very potent and selective at antagonizing responses mediated by NMDA receptor activation in 30 the mammalian CNS (Mueller et al., Effects of polyamine spider toxins on NMDA receptor-mediated transmission in rat hippocampus *in vitro*. *Soc. Neurosci. Abst.* 15: 945, 1989; Mueller et al., Arylamine spider toxins antagonize NMDA receptor-mediated synaptic transmission in rat 35 hippocampal slices. *Synapse* 9: 244, 1991; Parks et al., Polyamine spider toxins block NMDA receptor-mediated increases in cytosolic calcium in cerebellar granule

WO 95/21612

PCT/US94/12293

neurons. *Soc. Neurosci. Abst.* 15: 1169, 1989; Parks et al., Arylamine toxins from funnel-web spider (*Agelenopsis aperta*) venom antagonize N-methyl-D-aspartate receptor function in mammalian brain. *J. Biol. Chem.* 266: 21523, 5 1991; Priestley et al., Antagonism of responses to excitatory amino acids on rat cortical neurones by the spider toxin, argiotoxin-636. *Br. J. Pharmacol.* 97: 1315, 1989; Draguhn et al., Argiotoxin-636 inhibits NMDA-activated ion channels expressed in *Xenopus* oocytes. *Neurosci. Lett.* 10 132: 187, 1991; Kiskin et al., A highly potent and selective N-methyl-D-aspartate receptor antagonist from the venom of the *Agelenopsis aperta* spider. *Neuroscience* 51: 11, 1992; Brackley et al., Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins. *J. Pharmacol. Exp. Therap.* 266: 1573, 15 1993; Williams, Effects of *Agelenopsis aperta* toxins on the N-methyl-D-aspartate receptor: Polyamine-like and high-affinity antagonist actions. *J. Pharmacol. Exp. Therap.* 266: 231, 1993). Inhibition of nicotinic cholinergic receptors by the arylalkylamine toxin philanthotoxin has also been reported (Rozental et al., Allosteric inhibition of nicotinic acetylcholine receptors of vertebrates and insects by philanthotoxin. *J. Pharmacol. Exp. Therap.* 20 249: 123, 1989).

25 Parks et al. (Arylamine toxins from funnel-web spider (*Agelenopsis aperta*) venom antagonize N-methyl-D-aspartate receptor function in mammalian brain. *J. Biol. Chem.* 266: 21523, 1991), describe arylalkylamine spider toxins (α -agatoxins) which antagonize NMDA receptor function in 30 mammalian brain. The authors discuss the mechanism of action of arylalkylamine toxins, and indicate that an NMDA receptor-operated ion channel is the probable site of action of the α -agatoxins, and most probably other spider venom arylalkylamines. They state:

35 "The discovery that endogenous polyamines in the vertebrate brain modulate the function of NMDA receptors suggests that the arylamine toxins may

WO 95/21612

PCT/US94/12293

10

produce their antagonism via a polyamine-binding site on glutamate receptors. Brackley et al. studied the effects of spermine and philanthotoxin 433 on the responses evoked by application 5 of excitatory amino acids in *Xenopus* oocytes injected with mRNA from rat or chick brain. These authors reported that, at concentrations below those that antagonize glutamate receptor function, both spermine and philanthotoxin 10 potentiate the effects of excitatory amino acids and some other neurotransmitters. On the basis of these and other data, Brackley et al. concluded that the arylamine toxins may, by binding nonspecifically to the membranes of excitable 15 cells, reduce membrane fluidity and alter receptor function. The validity of this intriguing idea for NMDA receptor function is not well supported by two recent binding studies. Reynolds reported that argiotoxin 636 20 inhibits the binding of [³H]MK-801 to rat brain membranes in a manner that is insensitive to glutamate, glycine, or spermidine. This author concluded that argiotoxin 636 exerts a novel inhibitory effect on the NMDA receptor complex 25 by binding to one of the Mg²⁺ sites located within the NMDA-gated ion channel. Binding data reported by Williams et al. also support the conclusion that argiotoxin 636 does not act primarily at the polyamine modulatory site on 30 the NMDA receptor, but rather acts directly to produce an activity-dependent block of the ion channel. It is already known that compounds such as phencyclidine and ketamine can block the ion channels associated with both arthropod 35 muscle glutamate receptors and mammalian NMDA receptors. Thus, it seems possible that vertebrate and invertebrate glutamate receptors share

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

11

additional binding sites for allosteric modulators of receptor function, perhaps related to divalent cation-binding sites. Clearly, considerable additional work will be needed to determine if the arylamines define such a novel regulatory site."

Usherwood and Blagbrough (Spider Toxins Affecting Glutamate Receptors: Polyamines in Therapeutic Neurochemistry. *Pharmacol. Therap.* 52: 245, 1991) describe a proposed intracellular binding site for arylalkylamine toxins (polyamine amide toxins) located within the membrane potential field referred to as the QUIS-R channel selectivity filter. The authors postulate that the binding site for polyamine amide toxins may occur close to the internal entrance of the channel gated by the QUIS-R of locust muscle. The authors also note that one such toxin, argiotoxin-636, selectively antagonizes the NMDA receptor in cultured rat cortical neurons.

Gullak et al. (CNS binding sites of the novel NMDA antagonist Arg-636. *Soc. Neurosci. Abst.* 15: 1168, 1989), describe argiotoxin-636 (Arg-636) as a polyamine (arylalkylamine) toxin component of a spider venom. This toxin is said to block NMDA-induced elevation of cGMP in a noncompetitive fashion. The authors state that:

"[¹²⁵I]Arg-636 bound to rat forebrain membranes with K_d and B_{max} values of 11.25 μM and 28.95 pmol/mg protein (80% specific). The ability of other known polyamines and recently discovered polyamines from *Agelenopsis aperta* to inhibit binding paralleled neuroactivity as functional NMDA antagonists. No other compounds tested were able to block specific binding."

The authors then stated that polyamines (arylalkylamines) may antagonize responses to NMDA by interacting with membrane ion channels.

Seymour and Mena (*In vivo* NMDA antagonist activity of the polyamine spider venom component, argiotoxin-636.

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

12

Soc. Neurosci. Abst. 15: 1168, 1989) describe studies that are said to show that argiotoxin-636 does not significantly affect locomotor activity at doses that are effective against audiogenic seizures in DBA/2 mice, and 5 that it significantly antagonizes NMDA-induced seizures with a minimal effective dose of 32 mg/kg given subcutaneously (s.c.).

Herold and Yaksh (Anesthesia and muscle relaxation with intrathecal injections of AR636 and AG489, two 10 acylpolyamine spider toxins, in rats. Anesthesiology 77: 507, 1992) describe studies that are said to show that the arylalkylamine argiotoxin-636 (AR636), but not agatoxin-489 (AG489), produces muscle relaxation and anesthesia following intrathecal administration in rats.

15 Williams (Effects of *Agelenopsis aperta* toxins on the N-methyl-D-aspartate receptor: Polyamine-like and high-affinity antagonist actions, J. Pharmacol. Exp. Therap. 266: 231, 1993) reports that the α -agatoxins (arylalkylamines) Agel-489 and Agel-505 enhance the binding of 20 [3 H]MK-801 to NMDA receptors on membranes prepared from rat brain by an action at the stimulatory polyamine receptor; polyamine receptor agonists occluded the stimulatory effects of Agel-489 and Agel-505 and polyamine receptor antagonists inhibited the stimulatory effect of Agel-505. 25 Higher concentrations of Agel-489 and Agel-505, and argiotoxin-636 at all concentrations tested, had inhibitory effects on the binding of [3 H]MK-801. In *Xenopus* oocytes voltage-clamped at -70 mV, Agel-505 inhibited responses to NMDA with an IC₅₀ of 13 nM; this effect of 30 Agel-505 occurred at concentrations approximately 10,000-fold lower than those that affected [3 H]MK-801 binding. Responses to kainate were inhibited only 11% by 30 nM Agel-505. The antagonism of NMDA-induced currents by Agel-505 was strongly voltage-dependent, consistent with 35 an open-channel blocking effect of the toxin. Williams states:

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

13

"Although α -agatoxins can interact at the positive allosteric polyamine site on the NMDA receptor, stimulatory effects produced by this interaction may be masked in functional assays due to a separate action of the toxins as high-affinity, noncompetitive antagonists of the receptor."

Brackley et al. (Selective antagonism of native and cloned kainate and NMDA receptors by polyamine-containing toxins, *J. Pharmacol. Exp. Therap.* 266: 1573, 1993) report that the polyamine-containing toxins (arylalkylamines) philanthotoxin-343 (PhTX-343) and argiotoxin-636 (Arg-636) produce reversible, noncompetitive, partly voltage-dependent antagonism of kainate- and NMDA-induced currents in *Xenopus* oocytes injected with rat brain RNA. Arg-636 was demonstrated to be selective for NMDA-induced responses ($IC_{50} = 0.04 \mu M$) compared to kainate-induced responses ($IC_{50} = 0.07 \mu M$), while PhTX-343 was selective for kainate-induced responses ($IC_{50} = 0.12 \mu M$) compared to NMDA-induced responses ($IC_{50} = 2.5 \mu M$). Arg-636 more potently antagonized responses to NMDA in *Xenopus* oocytes expressing cloned NMDAR1 subunits ($IC_{50} = 0.09 \mu M$) than responses to kainate in oocytes expressing either cloned GluR1 ($IC_{50} = 3.4 \mu M$) or GluR1+GluR2 subunits ($IC_{50} \approx 300 \mu M$). PhTX-343, on the other hand, was equipotent at antagonizing NMDAR1 ($IC_{50} = 2.19 \mu M$) and GluR1 ($IC_{50} = 2.8 \mu M$), but much less potent against GluR1+GluR2 subunits ($IC_{50} = 270 \mu M$).

Raditsch et al. (Subunit-specific block of cloned NMDA receptors by argiotoxin-636. *FEBS Lett.* 324: 63, 1993) report that Arg-636 more potently antagonizes responses in *Xenopus* oocytes expressing NMDAR1+NMDAR2A subunits ($IC_{50} = 9 \text{ nM}$) or NMDAR1+NMDAR2B subunits ($IC_{50} = 2.5 \text{ nM}$) than NMDAR1+NMDAR2C subunits ($IC_{50} = 460 \text{ nM}$), even though all of the receptor subunits contain an asparagine residue in the putative pore-forming transmembrane region II (the Q/R site, as discussed above). The authors state

WO 95/21612

PCT/US94/12293

14

that the large difference in Arg-636 sensitivity between NMDAR1+NMDAR2A and NMDAR1+NMDAR2C channels "must be conferred by other structural determinants."

Herlitz et al. (Argiotoxin detects molecular differences in AMPA receptor channels. *Neuron* 10: 1131, 1993) report that Arg-636 antagonizes subtypes of AMPA receptors in a voltage- and use-dependent manner consistent with open-channel blockade. Arg-636 potently antagonizes Ca^{2+} -permeable AMPA receptors comprised of GluRAi ($K_i = 0.35 \mu\text{M}$), GluRCi ($K_i = 0.23 \mu\text{M}$), or GluRDi subunits ($K_i = 0.43 \mu\text{M}$), while being essentially ineffective against Ca^{2+} -impermeable GluRBi subunits at concentrations up to 10 μM . Other data reported by these investigators strongly suggest that the Q/R site in the putative pore-forming transmembrane region II is of primary importance in determining Arg-636 potency and Ca^{2+} permeability.

Blaschke et al. (A single amino acid determines the subunit-specific spider toxin block of α -amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor channels. *Proc. Natl. Acad. Sci. USA* 90: 6528, 1993) report that the arylalkylamine JSTX-3 potently antagonizes responses to kainate in *Xenopus* oocytes expressing GluR1 ($IC_{50} = 0.04 \mu\text{M}$) or GluR3 ($IC_{50} = 0.03 \mu\text{M}$) subunits, but that expressed receptors in which a GluR2 subunit is present are essentially unaffected by the toxin. Site-directed mutagenesis studies strongly implicate the Q/R site as the primary site influencing toxin potency.

Nakanishi et al. (Bioorganic studies of transmitter receptors with philanthotoxin analogs. *Pure Appl. Chem.*, 30 in press) have synthesized a number of highly potent photoaffinity labeled philanthotoxin (PhTX) analogs. Such analogs have been studied on expressed nicotinic cholinergic receptors as a model system for receptor-operated calcium channels receptors. These investigators suggest that these PhTX analogs block the ion channel with the hydrophobic headpiece of the toxin binding to a site near

WO 95/21612

PCT/US94/12293

15

the cytoplasmic surface while the polyamine tail extends into the ion channel from the cytoplasmic side.

Summary of the Invention

Applicant has examined the structural diversity and 5 biological activity of arylalkylamines (sometimes referred to as arylamine toxins, polyamine toxins, acylpolyamine toxins or polyamine amide toxins) in spider and wasp venoms, and determined that some of the arylalkylamines present in these venoms act as potent noncompetitive 10 antagonists of glutamate receptor-operated Ca^{2+} channels in the mammalian CNS. Although these arylalkylamine compounds contain within their structure a polyamine moiety, they are unlike other known simple polyamines in possessing extremely potent and specific effects on certain types 15 of receptor-operated Ca^{2+} channels.

Using native arylalkylamines as lead structures, a number of analogs were synthesized and tested. Initial findings on arylalkylamines isolated and purified from venom were confirmed utilizing synthetic arylalkylamines. 20 These compounds are small molecules (mol. wt. <800) with demonstrated efficacy in *in vivo* models of stroke and epilepsy. The NMDA receptor-ionophore complex was used as a model of receptor-operated Ca^{2+} channels. Selected arylalkylamines were shown to block NMDA receptor-mediated 25 responses by a novel mechanism. Moreover, the unique behavioral pharmacological profile of these compounds suggests that they are unlikely to cause the PCP-like psychotomimetic activity and cognitive deficits that characterize other inhibitors of the NMDA receptor. 30 Finally, the arylalkylamines are unique amongst NMDA receptor antagonists in that they are able to antagonize certain subtypes of cloned and expressed AMPA receptors, namely, those permeable to Ca^{2+} . The arylalkylamines, therefore, are the only known class of compounds able to 35 antagonize glutamate receptor-mediated increases in cytosolic Ca^{2+} regardless of the pharmacological definition of

WO 95/21612

PCT/US94/12293

16

receptor subtype. Additionally, the arylalkylamines inhibit another receptor-operated Ca^{2+} channel, the nicotinic cholinergic receptor. Given that excessive and prolonged increases in cytosolic Ca^{2+} have been implicated 5 in the etiology of several neurological disorders and diseases, such arylalkylamines are valuable small molecule leads for the development of novel therapeutics for various neurological disorders and diseases.




Applicant has determined that the selected arylalkyl-
10 amines bind with high affinity at a novel site on the NMDA receptor-ionophore complex which has heretofore been unidentified, and that said arylalkylamines do not bind with high affinity at any of the known sites (glutamate binding site, glycine binding site, MK-801 binding site,
15 Mg^{2+} binding site, Zn^{2+} binding site, polyamine binding site, sigma binding site) on said NMDA receptor-ionophore complex. This determination has allowed applicant to develop methods and protocols by which useful compounds can be identified which provide both therapeutically.
20 useful compounds and lead compounds for the development of other therapeutically useful compounds. These compounds can be identified by screening for compounds that bind at this novel arylalkylamine binding site, and by determining whether such a compound has the required biological,
25 pharmacological and physiological properties.

Thus, in a first aspect, the invention features a method for screening for a therapeutically useful compound active at one or more receptor-operated Ca^{2+} channels, as a noncompetitive antagonist. Such a compound may alterna-
30 tively or in addition be useful as a biopesticide or a pharmacological tool. The method includes the step of identifying a compound which binds to the receptor-operated Ca^{2+} channel at that site bound by the arylalkyl-amine compounds referred to herein as Compound 1, Compound
35 2 or Compound 3, and having the structures shown below.

WO 95/21612

PCT/US94/12293

17



In preferred embodiments, the invention features a method to identify one or more compounds active at a receptor-operated calcium channel which is part of an NMDA receptor-ionophore complex, part of a calcium-permeable AMPA receptor-ionophore complex, or part of a nicotinic cholinergic receptor-ionophore complex, and where the therapeutic use is for treatment of a neurological disorder or disease, or as a neuroprotectant, anticonvulsant, anxiolytic, analgesic, muscle relaxant or adjunct in general anesthesia.

By "therapeutically useful compound" is meant a compound that is potentially useful in the treatment of a disorder or disease state. A compound uncovered by the screening method is characterized as having potential therapeutic utility in treatment because clinical tests have not yet been conducted to determine actual therapeutic utility.

By "neurological disorder or disease" is meant a disorder or disease of the nervous system including, but not limited to, global and focal ischemic and hemorrhagic

WO 95/21612

PCT/US94/12293

18

stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage as in cardiac arrest or neonatal distress, epilepsy, anxiety, and neurodegenerative disease. Also meant by "neurological disorder or disease" are those 5 disease states and conditions in which a neuroprotectant, anticonvulsant, anxiolytic, analgesic, muscle relaxant and/or adjunct in general anesthesia may be indicated, useful, recommended or prescribed.

By "neurodegenerative disease" is meant diseases 10 including, but not limited to, Alzheimer's Disease, Huntington's Disease, and Parkinson's Disease.

By "neuroprotectant" is meant a compound capable of preventing the neuronal death associated with a neurological disorder or disease.

15 By "anticonvulsant" is meant a compound capable of reducing convulsions produced by conditions such as simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as occur following head injury, including head surgery.

20 By "anxiolytic" is means a compound capable of relieving the feelings of apprehension, uncertainty and fear that are characteristic of anxiety.

By "analgesic" is meant a compound capable of 25 relieving pain by altering perception of nociceptive stimuli without producing anesthesia or loss of consciousness.

By "muscle relaxant" is meant a compound that reduces muscular tension.

30 By "adjunct in general anesthesia" is meant a compound useful in conjunction with anesthetic agents in producing the loss of ability to perceive pain associated with the loss of consciousness.

In a related aspect the invention features a method for treating a neurological disease or disorder, comprising 35 the step of administering a pharmaceutical composition comprising a compound which binds to a receptor-operated calcium channel at the site bound by one of the arylalkyl-

WO 95/21612

PCT/US94/12293

19

amines Compound 1, Compound 2 and Compound 3, said compound being a potent and selective noncompetitive antagonist at such a receptor-operated calcium channel, and having one or more of the following pharmacological and physiological properties: efficacy in *in vitro* biochemical and electrophysiological assays of receptor-operated calcium channel function, *in vivo* anticonvulsant activity, *in vivo* neuroprotectant activity, *in vivo* anxiolytic activity, and *in vivo* analgesic activity; said compound also possessing one or more of the following pharmacological effects: the compound does not interfere with the induction of long-term potentiation in rat hippocampal slices, and, at a therapeutic dose, does not impair cognition, does not disrupt motor performance, does not produce neuronal vacuolization, has minimal cardiovascular activity, does not produce sedation or hyperexcitability, has minimal PCP-like abuse potential, and has minimal PCP-like psychotomimetic activity. By "minimal" is meant that any side effect of the drug is tolerated by an average individual, and thus that the drug can be used for therapy of the target disease. Such side effects are well known in the art and are routinely regarded by the FDA as minimal when it approves a drug for a target disease.

Treatment involves the steps of first identifying a patient that suffers from a neurological disease or disorder by standard clinical methodology and then treating such a patient with a composition of the present invention.

By "potent" is meant that the compound has at receptor-operated calcium channels, including NMDA receptors, Ca^{2+} -permeable AMPA receptors, and nicotinic cholinergic receptors, an IC_{50} value less than 10 μM , more preferably less than 100 nM, and even more preferably less than 1 nM.

By "selective" is meant that the compound is potent at receptor-operated calcium channels as defined above, but is less potent by greater than 10-fold, more prefer-

WO 95/21612

PCT/US94/12293

20

ably 50-fold, and even more preferably 100-fold, at other neurotransmitter receptors, neurotransmitter receptor-operated ion channels, or voltage-dependent ion channels.

By "biochemical and electrophysiological assays of receptor-operated calcium channel function" is meant assays designed to detect by biochemical or electrophysiological means the functional activity of receptor-operated calcium channels. Examples of such assays include, but are not limited to, the fura-2 fluorimetric assay for cytosolic calcium in cultured rat cerebellar granule cells (see Example 1 and Example 2), patch clamp electrophysiological assays (see Example 3 and Example 27), rat hippocampal slice synaptic transmission assays (see Example 5), radioligand binding assays (see Example 4, Example 24, Example 25, and Example 26), and *in vitro* neuroprotectant assays (see Example 6).

By "efficacy" is meant that a statistically significant level of the desired activity is detectable with a chosen compound; by "significant" is meant a statistical significance at the $p < 0.05$ level.

By "neuroprotectant activity" is meant efficacy in treatment of neurological disorders or diseases including, but not limited to, global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage as in cardiac arrest or neonatal distress, and neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, and Parkinson's Disease (see Examples 7 and 8, below).

By "anticonvulsant activity" is meant efficacy in reducing convulsions produced by conditions such as simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as occur following head injury, including head surgery (see Examples 9 and 10, below).

By "anxiolytic activity" is meant that a compound reduces the feelings of apprehension, uncertainty and fear that are characteristic of anxiety.

WO 95/21612

PCT/US94/12293

21

By "analgesic activity" is meant that a compound produces the absence of pain in response to a stimulus that would normally be painful. Such activity would be useful in clinical conditions of acute and chronic pain including, but not limited to the following: preemptive preoperative analgesia; peripheral neuropathies such as occur with diabetes mellitus and multiple sclerosis; phantom limb pain; causalgia; neuralgias such as occur with herpes zoster; central pain such as that seen with spinal cord lesions; hyperalgesia; and allodynia. By "causalgia" is meant a painful disorder associated with injury of peripheral nerves. By "neuralgia" is meant pain in the distribution of a nerve or nerves. By "central pain" is meant pain associated with a lesion of the central nervous system. By "hyperalgesia" is meant an increased response to a stimulus that is normally painful. By "allodynia" is meant pain due to a stimulus that does not normally provoke pain (see Examples 11 through 14, below).

By "induction of long term potentiation in rat hippocampal slices" is meant the ability of tetanic electrical stimulation of afferent Schaffer collateral fibers to elicit long-term increases in the strength of synaptic transmission at the Schaffer collateral-CA1 pyramidal cell pathway in rat hippocampal slices maintained *in vitro* (see Example 19).

By "therapeutic dose" is meant an amount of a compound that relieves to some extent one or more symptoms of the disease or condition of the patient. Additionally, by "therapeutic dose" is meant an amount that returns to normal, either partially or completely, physiological or biochemical parameters associated or causative of the disease or condition. Generally, it is an amount between about 1 nmole and 1 umole of the compound, dependent on its EC₅₀ (IC₅₀ in the case of an antagonist) and on the age, size, and disease associated with the patient.

WO 95/21612

PCT/US94/12293

22

By "impair cognition" is meant the ability to impair the acquisition of memory or the performance of a learned task (see Example 20). Also by "impair cognition" is meant the ability to interfere with normal rational thought processes and reasoning.

By "disrupt motor function" is meant the ability to significantly alter locomotor activity (see Example 15) or elicit significant ataxia, loss of the righting reflex, sedation or muscle relaxation (see Example 16).

10 By "locomotor activity" is meant the ability to perform normal ambulatory movements.

By "loss of the righting reflex" is meant the ability of an animal, typically a rodent, to right itself after being placed in a supine position.

15 By "neuronal vacuolization" is meant the production of vacuoles in neurons of the cingulate cortex or retrosplenial cortex (see Example 18).

By "cardiovascular activity" is meant the ability to elicit significant changes in parameters including, but 20 not limited to, mean arterial blood pressure and heart rate (see Examples 21 and 22).

By "hyperexcitability" is meant an enhanced susceptibility to an excitatory stimulus. Hyperexcitability is often manifested as a significant increase in locomotor 25 activity in rodents administered a drug (see Example 15).

By "sedation" is meant a calmative effect, or the allaying of activity and excitement. Sedation is often manifested as a significant decrease in locomotor activity in rodents administered a drug (see Example 15).

30 By "PCP-like abuse potential" is meant the potential of a drug to be wrongfully used, as in the recreational use of PCP (i.e., "angel dust") by man. It is believed that PCP-like abuse potential can be predicted by the ability of a drug to generalize to PCP in rodents trained 35 to discriminate PCP from saline (see Example 17.)

By "PCP-like psychotomimetic activity" is meant the ability of a drug to elicit in man a behavioral syndrome

WO 95/21612

PCT/US94/12293


23

resembling acute psychosis, including visual hallucinations, paranoia, agitation, and confusion. It is believed that PCP-like psychotomimetic activity can be predicted in rodents by the ability of a drug to produce PCP-like stereotypic behaviors including ataxia, head weaving, hyperexcitability, and generalization to PCP in rodents trained to discriminate PCP from saline (see Example 15, Example 16, and Example 17).

By "ataxia" is meant a deficit in muscular coordination.

By "head weaving" is meant the stereotypic behavior elicited in rodents by PCP in which the head is repeatedly moved slowly and broadly from side to side.

In a further aspect, the invention features compounds useful for treating a patient having a neurological disease or disorder wherein said compound is a polyamine-type compound or an analog thereof (i.e., a polyheteroatomic molecule) having the formula



wherein Ar is an appropriately substituted aromatic ring, ring system or other hydrophobic entity; Ar can be an aromatic (e.g., carbocyclic aryl groups such as phenyl and bicyclic carbocyclic aryl ring systems such as naphthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, and indenyl), heteroaromatic (e.g. indolyl, dihydroindolyl, quinolinyl and isoquinolinyl, and their respective 1,2,3, 4-tetrahydro- and 2-oxo- derivatives), alicyclic (cycloaliphatic), or heteroalicyclic ring or ring system (mono-, bi-, or tricyclic), having 5- to 7-membered ring(s) optionally substituted with 1 to 5 substituents independently selected from lower alkyl of 1 to 5 carbon atoms, lower haloalkyl of 1 to 5 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 5 carbon atoms, halogen, nitro, amino, lower alkylamino of 1 to 5 carbon

WO 95/21612

PCT/US94/12293

24

atoms, amido, lower alkylamido of 1 to 5 carbon atoms, cyano, hydroxyl, sulfhydryl, lower acyl of 2 to 4 carbon atoms, sulfonamido, lower alkylsulfonamido of 1 to 5 carbon atoms, lower alkylsulfoxide of 1 to 5 carbon atoms,
 5 lower hydroxyalkyl of 1 to 5 carbon atoms, lower alkylketo of 1 to 5 carbon atoms, or lower thioalkyl of 1 to 5 carbon atoms,


each m is an integer from 0 to 3, inclusive,
 each k is an integer from 1 to 10, inclusive,
 10 each j is the same or different and is an integer from 1 to 12, inclusive,

each R¹ and R² independently is selected from the group consisting of hydrogen, lower alkyl of 1 to 5 carbon atoms, lower alkylamino of 1 to 5 carbon atoms, lower alkylamido of 1 to 5 carbon atoms, lower mono-, di-, or trifluoroalkyl of 1 to 5 carbon atoms, hydroxy, amidino, guanidino, or typical common amino acid side chain or with an associated carbon atom R¹ and R² taken together form a carbonyl, and
 15

20 each Z is selected from the group consisting of nitrogen, oxygen, sulfur, amido, sulfonamido, and carbon.

Especially preferred are those embodiments in which the terminal -NR¹R² group is N-ethyl (R¹ = H, R² = CH₂CH₃), as these compounds are associated with a greatly reduced
 25 incidence and severity of undesirable cardiovascular side effects, such as hypotension.

Preferred aromatic headgroups include, but are not limited to, the following:




Headgroup A


WO 95/21612

PCT/US94/12293


25




Headgroup B



Headgroup C




Headgroup D



Headgroup E



Headgroup F



Headgroup G

where $Y = \frac{R^1}{R^2} - (C)_m - CO - NR^1 - \frac{R^1}{R^2} - [ZR^1 - \frac{R^1}{R^2}]_j]_k - N \begin{cases} R^1 \\ R^2 \end{cases}$

SUBSTITUTE SHEET (RULE 26)


WO 95/21612

PCT/US94/12293


26

Excluded from the present invention are known compounds whose chemical structures are covered by the generic formula presented above.


In further preferred embodiments, the compound is
5 selected from the group of Compounds 4 through 18, where such compounds have the formulae:




Compound 4



Compound 5



Compound 6









Compound 7

WO 95/21612

PCT/US94/12293






27



WO 95/21612

PCT/US94/12293

28



The invention also features compositions of the various compounds of the invention, including Compounds 4 - 18, or pharmaceutically acceptable salts thereof and pharmaceutical compositions or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier and dose.

By "pharmaceutical composition" is meant a therapeutically effective amount of a compound of the present invention in a pharmaceutically acceptable carrier, i.e., a formulation to which the compound can be added to dissolve or otherwise facilitate administration of the compound. Examples of pharmaceutically acceptable carriers include water, saline, and physiologically

WO 95/21612

PCT/US94/12293

29

buffered saline. Such a pharmaceutical composition is provided in a suitable dose. Such compositions are generally those which are approved for use in treatment of a specified disorder by the FDA or its equivalent in non-
5 U.S. countries.


Applicant has also determined (see Example 23 below) that simplified arylalkylamines (see below) are potent, noncompetitive antagonists of the NMDA receptor-ionophore complex. The simplified arylalkylamines are distinct from
10 the arylalkylamines exemplified by Compounds 4 - 18 as described above. For example, such compounds bind to the site labeled by [³H]MK-801 at concentrations ranging approximately 1 to 50-fold higher than those which antagonize NMDA receptor-mediated function. Such simplified
15 arylalkylamines possess one or more of the following additional biological properties: significant neuroprotectant activity, significant anticonvulsant activity, significant analgesic activity, no PCP-like stereotypic behavior in rodents (hyperexcitability and head weaving) at effective
20 neuroprotectant, anticonvulsant and analgesic doses, no generalization to PCP in a PCP discrimination assay at effective neuroprotectant, anticonvulsant and analgesic doses, no neuronal vacuolization at effective neuropro-
25 tectant, anticonvulsant and analgesic doses, significantly less potent activity against voltage-sensitive calcium channels, and minimal hypotensive activity at effective neuroprotectant, anticonvulsant and analgesic doses. Such compounds may, however, inhibit the induction of LTP in rat hippocampal slices and may produce motor impairment at
30 neuroprotectant, anticonvulsant and analgesic doses.

In a further aspect, the invention features a method for treating a patient having a neurological disease or disorder comprising administering a pharmaceutical composition comprising the following structure:


WO 95/21612

PCT/US94/12293



30





where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl or O-acyl, and each R² can be, independently, H or lower alkyl; or



- 5 where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl; or



- where n = 1-6, and each X can be, independently, one or
10 more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and R² can be H or lower alkyl; or



where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be

WO 95/21612


PCT/US94/12293

31


H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl.

Excluded from the present invention are known compounds whose chemical structures are covered by the 5 generic formulae presented above.


In preferred embodiments, the pharmaceutical compositions comprise Compounds 19 through 53, or pharmaceutically acceptable salts thereof.




Compound 19



Compound 20



Compound 21




Compound 22


WO 95/21612

PCT/US94/12293


32




Compound 23




Compound 24



Compound 25



Compound 26



Compound 27


WO 95/21612

PCT/US94/12293


33




Compound 28




Compound 29




Compound 30



Compound 31



Compound 32




Compound 33

WO 95/21612

PCT/US94/12293


34




Compound 34




Compound 35




Compound 36



Compound 37



Compound 38




Compound 39

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

35




Compound 40




Compound 41




Compound 42



Compound 43



Compound 44




Compound 45


WO 95/21612

PCT/US94/12293


36




Compound 46




Compound 47




Compound 48



Compound 49



Compound 50




Compound 51


WO 95/21612

PCT/US94/12293

37



Compound 52



Compound 53

Further preferred embodiments encompasses compositions comprising Compound 19 or a pharmaceutically acceptable salt thereof and pharmaceutical compositions or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier and dose.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Description of the Preferred Embodiments

10 The following is a detailed description of the methods and tests by which therapeutically useful compounds can be identified and utilized for treatment of neurological disorders and diseases. The tests are exemplified by use of Compound 1, Compound 2 or Compound 15 3, but other compounds which have similar biological activity in these assays can also be used (as discovered) to improve on the tests. Lead compounds such as Compound 1, Compound 2 or Compound 3 can be used for molecular modeling using standard procedures, or existing or novel 20 compounds in natural libraries can be screened by the methods described below.

One key method is the means by which compounds can be quickly screened with standard radioligand binding techniques (a radiolabeled arylalkylamine binding assay) to

WO 95/21612

PCT/US94/12293

identify those which bind at the same site on receptor-operated Ca^{2+} channels as Compound 1, Compound 2 or Compound 3. Data from such radioligand binding studies will also confirm that said compounds do not inhibit [3H]arylalkylamine binding via an action at the known sites on receptor-operated Ca^{2+} channels (such as the glutamate binding site, glycine binding site, MK-801 binding site, Zn^{2+} binding site, Mg^{2+} binding site, sigma binding site, or polyamine binding site on the NMDA receptor-ionophore complex). This screening test allows vast numbers of potentially useful compounds to be identified and screened for activity in the other assays. Those skilled in the art will recognize that other rapid assays for detection of binding to the arylalkylamine site on receptor-operated Ca^{2+} channels can be devised, and used in this invention.

Additional testing utilizes electrophysiological (patch clamp) methodology to extend the results obtained with the above-mentioned radioligand binding assay. Such results will confirm that compounds binding to the arylalkylamine site are functional, noncompetitive antagonists of receptor-operated Ca^{2+} channels with the following properties in common with the arylalkylamines themselves: open-channel block manifested as use-dependent block, and voltage-dependent onset and reversal from block. Such results will also confirm that said compounds do not have their primary activity at the previously described sites on receptor-operated Ca^{2+} channels (such as the glutamate binding site, glycine binding site, MK-801 binding site, Zn^{2+} binding site, Mg^{2+} binding site, sigma binding site, or polyamine binding site on the NMDA receptor-ionophore complex).

In addition, recombinant DNA technology can be used to make such testing even more rapid. For example, using standard procedures, the gene(s) encoding the novel arylalkylamine binding site (i.e., receptor) can be identified and cloned. This can be accomplished in one of several ways. For example, an arylalkylamine affinity column can

WO 95/21612

PCT/US94/12293

be prepared, and solubilized membranes from cells or tissues containing the arylalkylamine receptor passed over the column. The receptor molecules bind to the column and are thus isolated. Partial amino acid sequence information is then obtained which allows for the isolation of the gene encoding the receptor. Alternatively, cDNA expression libraries are prepared and subfractions of the library are tested for their ability to impart arylalkylamine receptors on cells which do not normally express such receptors (e.g., CHO cells, mouse L cells, HEK 293 cells, or *Xenopus* oocytes). In this way, the library fraction containing the clone encoding the receptor is identified. Sequential subfractionation of active library fractions and assay eventually results in a single clone encoding the arylalkylamine receptor. Similarly, hybrid-arrest or hybrid-depletion cloning can be used. *Xenopus* oocytes are injected with mRNA from an appropriate tissue or cell source (e.g., human brain tissue). Expression of the arylalkylamine receptor is detected as, for example, an NMDA- or glutamate-stimulated influx of calcium which can be blocked by Compound 1, Compound 2 or Compound 3. cDNA clones are tested for their ability to block expression of this receptor when cDNA or cRNA are hybridized to the mRNA of choice, prior to injection into *Xenopus* oocytes. The clone responsible for this effect is then isolated by the process described above. Once the receptor gene is isolated, standard techniques are used to identify the polypeptide or portion(s) thereof which is (are) sufficient for binding arylalkylamines (the arylalkylamine binding domain[s]). Further, using standard procedures, the entire receptor or arylalkylamine binding domain(s) can be expressed by recombinant technology. Said receptor or binding domain(s) can be isolated and used as a biochemical reagent such that, rather than using a competitive assay exemplified below, a simple direct binding assay can be used. That is, a screen is set up for compounds which bind at the novel arylalkylamine

WO 95/21612

PCT/US94/12293

40

receptor. In this way large numbers of compounds can be simultaneously screened, e.g., by passage through a column containing the novel arylalkylamine receptor or arylalkylamine binding domain, and analysis performed on compounds 5 which bind to the column.

Additional testing utilizes the combination of molecular biological techniques (expression of cloned NMDA, AMPA or nicotinic cholinergic receptors) and patch clamp electrophysiological techniques. Specifically, 10 arylalkylamine analogs can be rapidly screened for potency at cloned and expressed subunits of the above-mentioned receptor-ionophore complexes. Site-directed mutagenesis can be utilized in an effort to identify which amino acid residues may be important in determining arylalkylamine 15 potency.

Assays for Potent and Selective Antagonists of Receptor-Operated Calcium Channels in the Mammalian CNS

Desired properties of a drug include: high affinity and selectivity for receptor-operated Ca^{2+} channels, such 20 as those present in NMDA, AMPA and nicotinic cholinergic receptor-ionophore complexes (compared to responses mediated via other neurotransmitter receptors, neurotransmitter receptor-operated ion channels, or voltage-dependent ion channels) and a noncompetitive antagonism of 25 said receptor-operated Ca^{2+} channels.

The NMDA receptor-ionophore complex is utilized as an example of a receptor-operated Ca^{2+} channel. Activation of the NMDA receptor opens a cation-selective channel that allows the influx of extracellular Ca^{2+} and Na^+ , resulting 30 in increases in $[\text{Ca}^{2+}]_i$ and depolarization of the cell membrane. Measurements of $[\text{Ca}^{2+}]_i$ were used as primary assays for detecting the activity of arylalkylamine compounds on NMDA receptors. Purified arylalkylamines, synthetic aryl-alkylamines, and synthetic analogs of 35 arylalkylamines were examined for activity in *in vitro* assays capable of measuring glutamate receptor activity.

WO 95/21612

PCT/US94/12293

41

Selected for detailed study were the arylalkylamines present in the venom of various spider species. The arylalkylamines present in these venoms are structurally distinct but have the basic structure of the class represented by Compounds 1 through 3. Other more simplified synthetic analogs generally consist of suitably substituted aromatic chromophoric groups attached to an alkyl(poly)amine moiety (see Compounds 19 through 53 below).

A primary assay that provides a functional index of glutamate receptor activity and that allows high-throughput screening was developed. Primary cultures of rat cerebellar granule cells loaded with the fluorimetric indicator fura-2 were used to measure changes in $[Ca^{2+}]_i$ elicited by NMDA and its coagonist glycine. This assay provides an extremely sensitive and precise index of NMDA receptor activity. Increases in $[Ca^{2+}]_i$ evoked by NMDA are dependent on the presence of glycine, and are blocked by extracellular Mg^{2+} or antagonists acting at the glutamate, glycine, or MK-801 binding sites. Increases in $[Ca^{2+}]_i$ elicited by NMDA/glycine are readily distinguished from those resulting from depolarization by their refractoriness to inhibition by blockers of voltage-sensitive Ca^{2+} channels. The fidelity with which measurements of $[Ca^{2+}]_i$ corroborate results obtained by electrophysiological and ligand-binding studies suggests that such measurements mirror closely activation of the NMDA receptor-ionophore complex.

Example 1: Potent noncompetitive inhibition of NMDA receptor function

Preferential inhibitory effects of arylalkylamines on NMDA receptor-mediated increases in $[Ca^{2+}]_i$ in cultured rat cerebellar granule cells were measured. Increases in $[Ca^{2+}]_i$ were elicited by the addition of NMDA/glycine (50 $\mu M/1 \mu M$) in the presence or absence of different concentrations of each test compound. The IC_{50} values were

WO 95/21612

PCT/US94/12293

42

derived for each test compound using from 2 to 8 separate experiments per test compound, and the standard error level was less than 10% of the mean value for each compound.

5 All of the arylalkylamines tested blocked increases in $[Ca^{2+}]_i$ in cerebellar granule cells elicited by NMDA/glycine. Certain arylalkylamines similar in structure to Compound 1 or Compound 2 were nearly as potent as MK-801 ($IC_{50} = 34$ nM) which is the most potent compound in the literature known to preferentially block NMDA receptors.
10 Compound 3 had an $IC_{50} = 2$ nM, that is, 17-fold more potent than MK-801. Many of the arylalkylamines tested were more potent than competitive antagonists such as AP5 ($IC_{50} = 15$ μM). The inhibitory effects of the arylalkylamines were
15 not overcome by increasing the concentrations of NMDA or glycine. That is, no change was observed in the EC_{50} for either NMDA or glycine. The arylalkylamines are thus noncompetitive antagonists at the NMDA receptor-ionophore complex, and act neither at the glutamate nor the glycine
20 binding sites.

Example 2: Activity against Kainate and AMPA receptor function

Measurements of $[Ca^{2+}]_i$ in cerebellar granule cells can also be used to monitor activation of the native
25 kainate or AMPA receptors present in this tissue. Although the increases in $[Ca^{2+}]_i$ evoked by these agonists are of a lesser magnitude than those evoked by NMDA/glycine, such responses are robust and can be used to precisely assess the specificity of action of
30 arylalkylamines on pharmacologically defined glutamate receptor subtypes. Comparative measurements of $[Ca^{2+}]_i$ revealed a clear distinction in the receptor selectivity of the arylalkylamines. Some, like JSTX-3 (Joro Spider toxin from the spider *Nephila clavata*), were more potent
35 antagonists of responses elicited by kainate (100 μM) or AMPA (30 μM). On the other hand, arylalkylamines within

WO 95/21612

PCT/US94/12293

43

the two structural classes defined by Compound 1 and by Compound 2 were found to inhibit preferentially responses evoked by NMDA (showing about a 100-fold difference in potency). Thus, arylalkylamines such as Compound 1 and 5 Compound 2 are potent and selective inhibitors of NMDA receptor-mediated responses in cerebellar granule cells.

Example 3: Patch clamp electrophysiology studies

Patch clamp electrophysiological studies on isolated cortical or hippocampal neurons from adult rat brain have 10 provided additional insight into the mechanism of action of Compound 1, Compound 2 and Compound 3. These studies revealed potent and selective inhibitory effects of arylalkylamines on responses mediated by NMDA receptors. Thus, compounds such as Compound 1 blocked responses to 15 NMDA at nanomolar concentrations without affecting the responses to kainate. These results, which show selective inhibitory effects of the arylalkylamines in cortical and hippocampal neurons, indicate that the arylalkylamines target NMDA receptors in different regions within the 20 mammalian CNS. Moreover, it was found that the inhibitory effects of these compounds were use- and voltage-dependent. This strongly suggests that these compounds are blocking the open channel and, by this action, behave as noncompetitive NMDA receptor antagonists. Importantly, 25 however, the arylalkylamines could be distinguished from both Mg²⁺ and MK-801, especially with respect to the voltage-dependence of their onset of action and reversibility of effect.

Example 4: Radioligand binding assays

30 Radioligand binding studies have demonstrated that arylalkylamines such as Compound 1 and Compound 2 have a unique site of action. Although they act like MK-801 in some respects (noncompetitive open-channel blockade, discussed above), they fail to displace [³H]MK-801 binding 35 at concentrations that completely block NMDA receptor-

WO 95/21612

PCT/US94/12293

44

mediated responses. Assays such as these also demonstrate that the arylalkylamines do not bind with high affinity to the known MK-801, Mg²⁺, or polyamine binding sites on the NMDA receptor-ionophore complex. Neither do the arylalkylamines bind directly to either the glutamate, glycine or sigma binding sites at concentrations that block NMDA receptor-mediated responses. [³H]Compound 2 was synthesized as a radioligand for use in binding studies to further explore the mechanism of action of Compound 2 and particularly for use in a high-throughput screen to assess the activity of other analogs and to detect new lead structures. A similar approach was taken for [³H]Compound 5. It is clear that compounds like Compound 1 and Compound 2 target a site on the NMDA receptor-ionophore complex for which no other known compounds presently exist. The novel site of action of the arylalkylamines at the molecular level translates into pronounced therapeutic advantages at the behavioral level. As described below, the arylalkylamines possess a quite different behavioral profile from other noncompetitive antagonists of the NMDA receptor.

Example 5: Synaptic transmission studies

The above findings demonstrate that certain arylalkylamines, specifically those related in structure to Compound 1 and Compound 2, act through a novel mechanism and site of action to potently and selectively inhibit NMDA receptor-mediated responses on neurons from several different brain areas. To further assess the selective inhibitory actions of the arylalkylamines, their effects on synaptic transmission mediated by NMDA or AMPA receptors were assessed.

Glutamate-mediated transmission at synapses of Schaffer collateral fibers and CA1 pyramidal cells was measured in slices of rat brain containing the hippocampus. This assay measures electrophysiologically the postsynaptic depolarization caused by the presynaptic

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

45

release of glutamate, and can readily distinguish synaptic transmission mediated by NMDA or AMPA receptors. Arylalkylamines like Compound 1, Compound 2 and Compound 3 were again found to exert preferential inhibitory effects on NMDA receptor-mediated responses, and depressed responses mediated by AMPA receptors only at much higher concentrations. For example, Compound 1 had an IC₅₀ for the NMDA receptor-mediated response of 20 μM, but an IC₅₀ for the AMPA receptor-mediated response of 647 μM. These results show that arylalkylamines can selectively inhibit synaptic transmission mediated by NMDA receptors. Other naturally occurring arylalkylamines present in the venom of *Agelenopsis aperta* likewise exert potent and selective inhibitory effects on NMDA receptor-mediated responses in the rat hippocampus.

In the aggregate, then, the results of these various studies are complementary and together identify a structurally novel class of compounds with potent and selective inhibitory activity on NMDA receptors in the mammalian CNS. Additionally, these compounds target a unique site on the NMDA receptor-ionophore complex. Compound 1, Compound 2 and Compound 3 were selected for additional study in a variety of *in vitro* and *in vivo* assays that model therapeutically important endpoints.

25 Neuroprotectant activity

Desired properties of a neuroprotectant drug include the following. (1) The drug can be administered by oral or injectable routes (i.e., it is not significantly broken down in the stomach, intestine or vascular system and thus reaches the tissues to be treated in a therapeutically effective amount). Such drugs are easily tested in rodents to determine their bioavailability. (2) The drug exhibits neuroprotectant activity (i.e., efficacy) when given after an ischemic insult (stroke, asphyxia) or traumatic injury (head trauma, spinal cord injury). (3) The drug is devoid of or has minimal side effects such as

WO 95/21612

PCT/US94/12293

46

impairment of cognition, disruption of motor performance, sedation or hyperexcitability, neuronal vacuolization, cardiovascular activity, PCP-like abuse potential, or PCP-like psychotomimetic activity.

5 Although glutamate is the physiological synaptic transmitter, chronic exposure to glutamate leads to neuronal cell death. Much of the neurodegeneration caused by glutamate appears to be mediated by NMDA receptors and results directly from chronically elevated levels of
10 cytosolic Ca^{2+} . There is now extensive experimental support for the view that NMDA and AMPA receptors play a major role in mediating the neuronal degeneration following a stroke and other ischemic/hypoxic events (Choi,
15 Glutamate neurotoxicity and diseases of the nervous system. *Neuron* 1: 623, 1988). Most of this evidence is based on the ability of competitive or noncompetitive antagonists of the NMDA or AMPA receptor to effectively block neuronal cell death in both *in vitro* and *in vivo* models of stroke. Compound 1, Compound 2 and Compound 4
20 were therefore examined for neuroprotectant effects in standard assays designed to detect such activity.

Example 6: Cortical neuron protection

To assess the *in vitro* neuroprotectant effect of arylalkylamines, mouse cortical neurons grown in culture
25 were exposed for 5 minutes to NMDA, and cell death after 24 hours was monitored by measuring the release of lactate dehydrogenase (LDH), a cytoplasmic enzyme that is released from dying cells (Choi et al., Glutamate neurotoxicity in cortical cell culture. *J. Neurosci.* 7: 357, 1987).
30 Exposure to NMDA killed about 80% of the cortical neurons. Compound 1 or Compound 2, included along with NMDA, prevented cell death with IC_{50} values of 70 μM and 30 μM , respectively. The effective concentrations of the arylalkylamines are higher than those of other noncompetitive
35 NMDA receptor antagonists, but similar to those of competitive antagonists. The effective concentrations of

WO 95/21612

PCT/US94/12293

47

NMDA receptor antagonists vary depending on the particular experimental conditions and the type of cell studied (cortical, hippocampal, striatal). This neuroprotectant effect likely results from the ability of these compounds 5 to block the influx of extracellular Ca^{2+} triggered by the NMDA receptor.

More rigorous testing to determine potential therapeutic efficacy involved *in vivo* stroke models. In these models, the blood supply is temporarily blocked by clamping 10 the main arteries to the brain. Two *in vivo* models of this sort were used to determine the ability of Compound 1, Compound 2 and Compound 4 to prevent neuronal cell loss.

Example 7: Bilateral carotid artery occlusion

15 The first assay was the bilateral common carotid artery occlusion model of forebrain ischemia performed in the gerbil (Karpiak et al., Animal models for the study of drugs in ischemic stroke. *Ann. Rev. Pharmacol. Toxicol.* 29: 403, 1989; Ginsberg and Busto, Rodent models of 20 cerebral ischemia. *Stroke* 20: 1627, 1989). Blood flow to the brain was interrupted for 7 minutes by clamping the carotid arteries. The test compounds were administered as a single dose given intraperitoneally (i.p.) 30 minutes after reinstating blood flow. During the course of these 25 experiments, the core body temperature of the animals was maintained at 37°C to prevent any hypothermic reaction. It has been shown that many NMDA receptor antagonists cause hypothermia and this effect can account for much of the protective effect of these compounds. The brains were 30 examined for neuronal cell death 4 days later by silver staining sections of the brain and quantifying death by morphometric analysis. Compound 2 (20 mg/kg) significantly ($p < 0.05$) protected against neuronal cell death in all areas of the brain examined (region CA1 of hippocampus, striatum and neocortex). Doses as low as 1 mg/kg 35 afforded complete (>98%) protection of the striatum. The

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

48

degree of protection is comparable to that achieved with similar doses of the noncompetitive NMDA antagonist, MK-801.

In subsequent experiments, Compound 1 (10 mg/kg) produced a 23% reduction in the amount of neuronal death in region CA1 of the gerbil hippocampus measured at 7 days post-ischemia, while Compound 4 (10 mg/kg) provided 90% protection.

Example 8: Middle cerebral artery occlusion

The middle cerebral artery model of stroke performed in the rat (Karpiak et al., Animal models for the study of drugs in ischemic stroke. *Ann. Rev. Pharmacol. Toxicol.* 29: 403, 1989; Ginsberg and Busto, Rodent models of cerebral ischemia. *Stroke* 20: 1627, 1989) is different from the gerbil model because it results in a more restricted brain infarct, and thereby approximates a different kind of stroke (focal thrombotic stroke). In the first study using this stroke model, one cerebral artery was permanently occluded by surgical ligation. The test compounds were administered 30 minutes after the occlusion by a single intraperitoneal (i.p.) injection. During the course of these experiments, the core body temperature of the animals was maintained at 37°C to prevent any hypothermic reaction. Brains were assessed histologically for neuronal cell loss 24 hours later. Infarct volumes were calculated using the area of histological pallor from 10 slides and integrating the distance between each successive section. A single dose (30 mg/kg) of Compound 1 was found to significantly ($p < 0.05$) protect against neuronal cell loss equally as well as a maximally effective dose (10 mg/kg) of MK-801 (approximately 15% protection). Preliminary studies with Compound 2 (20 mg/kg) indicated a similar trend.

In the second study of focal cerebral ischemia in the rat, the middle cerebral artery was permanently occluded by passing a small piece of suture thread through the

WO 95/21612

PCT/US94/12293

carotid artery to the region of the middle cerebral artery. Core body temperature was maintained at 37°C. Compound 4, 10 mg/kg i.p. administered immediately after the onset of the ischemic event, produced a statistically significant reduction in the volume of the brain infarct (20%) recorded 24 hr later.

In a third model of focal cerebral ischemia in the rat, an ischemic infarct was produced by a photothrombotic method using the dye Rose Bengal. Compound 4, 10 mg/kg i.p. administered 30 min after the ischemic event, produced a 20% reduction in the volume of the infarct, similar to that seen with the noncompetitive NMDA receptor antagonist, MK-801.

In a fourth model of focal cerebral ischemia in the rat, the middle cerebral artery was temporarily occluded by passing a small piece of suture thread through the carotid artery to the region of the middle cerebral artery. The suture thread was withdrawn after an ischemic period of 2 hr. Core body temperature was maintained at 37°C. Compound 4 administered at 10 mg/kg i.p. immediately after the onset of the ischemic event, produced a statistically significant reduction in the volume of the brain infarct (37%) recorded 72 hr later.

Several important features of the lead compounds emerge from these *in vivo* results. First, and most importantly, Compound 1, Compound 2 and Compound 4 demonstrate neuroprotectant effects in several different *in vivo* models of stroke. The gerbil assay is a model for transient global cerebral ischemia and hypoxia such as cardiac arrest or perinatal hypoxia. The rat assays are models of permanent and temporary focal cerebral ischemia. The finding that Compound 1 and Compound 4 are neuroprotective in the permanent focal stroke models is surprising because the accessibility of the drug to the site of infarction is limited to the penumbral region which generally is not large. Nonetheless, Compound 1 and Compound 4 significantly ($p < 0.05$) limited the extent of damage.

WO 95/21612

PCT/US94/12293

50

Second, the compounds are effective when administered after the ischemic event. This is important because there is believed to be a "window of opportunity" following an infarct during which drugs may effectively halt necrotic damage. How long this time is in humans has not been defined precisely, and will likely vary depending upon the type of infarct. The essential observation, however, is that these compounds can prevent the spread of neuronal cell death once the degenerative process has commenced.

10 Finally, Compound 1, Compound 2 and Compound 4 are effective when administered parenterally, demonstrating that they penetrate the blood-brain barrier.

Anticonvulsant activity

Desired properties of an anticonvulsant drug include:

15 the drug can be administered by oral or injectable routes, the drug exhibits effective anticonvulsant activity against several seizure types, including, but not limited to, simple partial seizures, complex partial seizures, status epilepticus, and trauma-induced seizures such as

20 occur following head injury, including head surgery; and the drug is devoid of or has minimal side effects such as impairment of cognition, disruption of motor performance, sedation or hyperexcitability, neuronal vacuolization, cardiovascular activity, PCP-like abuse potential, or PCP-

25 like psychotomimetic activity.

Glutamate is the major excitatory transmitter in the brain, and thus may play a major role in seizure activity, and contribute to the pathogenesis of epilepsy. Much of the evidence favoring a major role for glutamate receptors

30 in epilepsy derives from pharmacological studies demonstrating that glutamate receptor agonists elicit seizures, and that NMDA and AMPA receptor antagonists are effective anticonvulsants when administered *in vivo*. There are numerous *in vivo* models involving different kinds of

35 seizures and behavioral effects that are relevant for clinically distinct forms of epilepsy. It is thus prudent

WO 95/21612

PCT/US94/12293

51

to test for effects in several models, because it may be an oversimplification to suppose that the same mechanism underlies all forms of seizure activity.

Example 9: Convulsant blocking activity

5 In initial studies, the ability of arylalkylamines to
block seizures induced by kainate, picrotoxin or bicucul-
line were examined. Each of these convulsants acts
through a different mechanism and seizures elicited by
kainate are qualitatively different from those elicited by
10 picrotoxin or bicuculline. In these experiments, a
fraction of *Agelenopsis aperta* venom containing several
arylalkylamine toxins was administered intravenously (iv)
5 min before picrotoxin or bicuculline, and 5 min after
kainate administration. The arylalkylamines diminished
15 the seizures induced by all three of these agents. The
effects of picrotoxin or bicuculline were so severe that
all 19 control animals died within 25 minutes. In con-
trast, there were no deaths in the 9 animals pretreated
with the arylalkylamines. In fact, only about half the
20 animals treated with the arylalkylamines showed any
convulsions at all and those symptoms abated within an
hour. These results demonstrate clear anticonvulsant
effects of arylalkylamines and prompted further studies
using purified arylalkylamines and their analogs.

25 Example 10: Seizure stimuli

Three different seizure-inducing test paradigms were used initially in this second group of studies and arylalkylamines such as Compound 1 proved to be effective anticonvulsants in two such paradigms. The first two
30 models used DBA/2 mice which are prone to audiogenic seizures. Seizures were elicited by sound (bell tone at 109 dBs) or the intraperitoneal (ip) administration of NMDA (56 mg/kg). The test substances were administered 15-30 min before the convulsant stimulus. The number of
35 clonic seizures was recorded for 1 min following the

WO 95/21612

PCT/US94/12293

audiogenic stimulus or for 15 min following the administration of NMDA. Compound 1, Compound 2, and several other arylalkylamines such as Compound 3 and Compound 4 depressed seizures evoked by either stimulus. For 5 example, Compound 2 had an ED₅₀ of 0.13 mg/kg s.c. for audiogenic stimulus and 0.083 mg/kg s.c. for NMDA stimulus. Similarly, the EC₅₀ for Compound 4 in the audiogenic seizure model (0.08 mg/kg) approached that for MK-801 (0.02 mg/kg). In contrast, neither Compound 1 nor 10 Compound 2 was effective at doses up to 50 mg/kg s.c. in reducing seizures in CF-1 mice elicited by i.p. NMDA.

In a second independent series of experiments, Compound 1 and Compound 4 were found to prevent seizures induced by sound in another genetically susceptible mouse 15 model of reflex epilepsy (Frings mice) following intraperitoneal injection with IC₅₀ values of 14.3 mg/kg and ~15 mg/kg, respectively. These compounds were considerably more potent against audiogenic seizures in Frings mice following intracerebroventricular (i.c.v.) injection, with 20 IC₅₀ values of 0.63 µg (Compound 1) and 4.77 µg (Compound 4). Compound 1 was also found to be effective against seizures elicited by maximal electroshock in CF1 mice at a dose of 4 µg i.c.v.

In further studies using the genetically susceptible 25 mouse model of reflex epilepsy (Frings mice), Compound 9, Compound 12 and Compound 14, administered by i.c.v. injection, prevented sound-induced seizures with IC₅₀ values of 4.77 µg, 12.2 µg and 13.9 µg, respectively.

These collective findings demonstrate that arylalkylamines such as Compound 1, Compound 2 and Compound 4 are 30 effective in preventing epileptic (audiogenic) and non-epileptic (chemoconvulsant) seizures. This generalized pattern of activity suggests that arylalkylamines are clinically useful in controlling seizure activity. In 35 addition, the potency of Compound 1, Compound 2 and especially Compound 4 in in vivo models of seizure activity shows that these compounds can have the thera-

WO 95/21612

PCT/US94/12293

53

apeutically relevant effects when administrated parenterally in low doses, and are especially potent when administered directly into the cerebral ventricles.

Analgesic activity

5 Desired properties of an analgesic drug include: the drug can be administered by oral or injectable routes, the drug exhibits analgesic activity, the drug is devoid of or has minimal side effects such as impairment of cognition, disruption of motor performance, sedation or hyperexcitability, neuronal vacuolization, cardiovascular activity, PCP-like abuse potential, or PCP-like psychotomimetic activity.

10 Glutamate and NMDA receptor-mediated responses may play a role in certain kinds of pain perception (Dickenson, A cure for wind up: NMDA receptor antagonists as potential analgesics. *Trends Pharmacol. Sci.* 11: 302, 1990). The possible analgesic effects of Compound 1, Compound 2, Compound 3 and Compound 4 were therefore examined.

20 Example 11: Writhing response test

In the first series of experiments, the animals were administered an unpleasant stimulus (2-phenyl-1,4-benzoquinone, PBQ) which elicits a writhing response (abdominal stretching). Typically, the number of writhes occurring in a 5 min observation period is recorded. Classic analgesic drugs, such as morphine, are effective at decreasing the number of PBQ-elicited writhes (100% block of the writhing response at 4 mg/kg i.p.). Nonsteroidal antiinflammatory agents are likewise effective in this model. Compound 1 (2 mg/kg), Compound 2 (2 mg/kg) and Compound 3 (1 mg/kg) depressed the writhing response by greater than 95% when administered s.c. or i.p. 30 minutes before PBQ. These results demonstrate that Compound 1, Compound 2 and Compound 3 alleviate visceral pain.

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

54

In a similar series of studies, Compound 1 and Compound 4 were found to inhibit acetic acid-induced writhing in mice following i.p. injection with IC₅₀ values of 10 mg/kg and 1 mg/kg, respectively.

5 Example 12: Hot plate test

Compound 1 was tested for analgesic activity in an additional assay. In this model of analgesic activity, mice were administered test substances s.c. 30 min before being placed on a hot plate (50°C). The time taken to lick 10 the feet or jump off the plate is an index of analgesic activity, and effective analgesics increase the latency to licking or jumping. Morphine (5.6 mg/kg) increased the latency to jump by 765%. Compound 1 was likewise effective in this assay and, at doses of 4 and 32 mg/kg, 15 increased the latency to foot licking by 136% and the latency to jumping by 360%, respectively.

It is noteworthy that the analgesic effects of Compound 1 in the hot plate assay were not accompanied by a decreased performance in the inverted grid assay (see 20 below). This shows that the increase in the latency to jump off the hot plate does not simply reflect impaired motor capabilities. Together, these data suggest that Compound 1 possesses significant analgesic activity.

In a later series of experiments, Compound 1 and 25 Compound 4 were demonstrated to possess significant analgesic activity in rats when administered by the intrathecal (i.th.) route. In these experiments, a 52°C hot plate was used as the nociceptive stimulus. Compound 1 (0.3 - 3 nmol) and Compound 4 (0.3 - 3 nmol) produced 30 dose- and time-dependent antinociceptive effects; these arylalkylamines were similar to morphine (0.3 - 3 nmol) in terms of potency and efficacy. The NMDA receptor antagonist, MK-801, on the other hand, was ineffective in this assay (3-30 nmol).

WO 95/21612

PCT/US94/12293

55

Example 13. Tail flick test

In this standard assay, the thermal nociceptive stimulus was 52°C warm water with the latency to tail flick or withdrawal taken as the endpoint. Compound 1 (0.3 - 3 nmol) and Compound 4 (0.3 - 3 nmol) produced a dose- and time-dependent analgesic effect following i.th. administration. These arylalkylamines were similar to morphine (0.3 - 3 nmol) in terms of potency and efficacy. The NMDA receptor antagonist, MK-801, on the other hand, 10 was ineffective in this assay (3-30 nmol).

Example 14. Formalin test

Male Sprague-Dawley rats were habituated to an observation chamber for at least 1 hr before receiving an injection of dilute formalin (5%) in a volume of 50 μ l 15 into the left rear paw. Behavioral responses were monitored immediately after s.c. injection of formalin into the dorsal surface of the paw by counting the number of flinches exhibited by the animal. Behaviors were monitored for at least 50 min after formalin injection and 20 were recorded as early phase responses (0 - 10 min post-formalin) and late phase responses (20 - 50 min post-formalin). Compounds were injected intrathecally (i.th.) 10 min prior to formalin (pre-treatment) or 10 min after formalin (post-treatment) in a volume of 5 μ l.

25 Intraplantal administration of formalin produced a typical biphasic response of flinching behavior, commonly described as the early and late phase responses. Intrathecal administration of Compound 1 (0.3 - 10 nmol) or Compound 4 (0.3 - 10 nmol) given as a pretreatment to 30 formalin effectively inhibited both early- and late-phase flinching behaviors. This effect of pretreatment with the arylalkylamines was similar to that seen with pretreatment with morphine (1 - 10 nmol) or MK-801 (1 - 30 nmol).

Compound 1 (0.3 - 10 nmol i.th.) administered after 35 the formalin produced some inhibition of late-phase flinching, though significance was achieved only at the 10

WO 95/21612

PCT/US94/12293

56

nmol dose. Compound 4 (0.3 - 10 nmol i.th.) administered after the formalin produced significant inhibition of late-phase flinching, with significance achieved at the 3 and 10 nmol doses. This analgesic profile of activity of 5 the arylalkylamines is similar to that seen with post-formalin administration of morphine (1 - 10 nmol); post-formalin administration of MK-801 (1 - 30 nmol), however, failed to affect late-phase flinching.

Taken together, the results obtained with the hot 10 plate, tail flick and formalin assays demonstrate that arylalkylamines such as Compound 1 and Compound 4 have significant analgesic activity in several rodent models of acute pain. The formalin assay additionally demonstrates that arylalkylamines are effective in an animal model of 15 chronic pain. Importantly, the arylalkylamines possess significant analgesic activity when administered after the formalin stimulus. This profile of activity clearly distinguishes the arylalkylamines from standard NMDA receptor antagonists such as MK-801.

20 Side effects of arylalkylamines

Given the important role NMDA receptors play in diverse brain functions, it is not surprising to find that antagonists of this receptor are typically associated with certain unwelcome side effects. In fact, it is this 25 property that provides the major obstacle to developing therapies that target NMDA receptors. The principal side effects, which characterize both competitive and noncompetitive antagonists, are a PCP-like psychotomimetic activity, impairment of motor performance, sedation or 30 hyperexcitability, impairment of cognitive abilities, neuronal vacuolization, or cardiovascular effects (Willettts et al., The behavioral pharmacology of NMDA receptor antagonists. *Trends Pharmacol. Sci.* 11: 423, 1990; Olney et al., Pathological changes induced in 35 cerebrocortical neurons by phencyclidine and related drugs. *Science* 244: 1360, 1989). The psychotomimetic

WO 95/21612

PCT/US94/12293

57

effect associated with inhibition of NMDA receptor-mediated responses is epitomized in the response to phencyclidine (PCP) or "angel dust" which acts at the MK-801 binding site. Impairment of cognitive ability is 5 associated with the important role that NMDA receptors normally play in learning and memory.

Relatively less is known concerning the side effect profile of AMPA receptor antagonists. However, it is becoming clear that such compounds also elicit motor 10 impairment, ataxia and profound sedation.

The activity of arylalkylamines was examined in animal models that index motor impairment, sedation and psychotomimetic activity as well as both *in vitro* and *in vivo* models of learning and memory.

15 (a) PCP-like Psychotomimetic Activity

In rodents, both competitive and noncompetitive antagonists of the NMDA receptor produce a PCP-like stereotypic behavior characterized by hyperactivity, head-weaving, and ataxia (Willettts et al., *The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci.* 11: 423, 1990; Snell and Johnson, In: *Excitatory Amino Acids in Health and Disease*, John Wiley & Sons, p. 261, 1988). We investigated whether the arylalkylamines would elicit such behaviors. In addition, we 20 investigated whether the arylalkylamines would substitute for PCP in rats trained to discriminate PCP from saline (Willettts et al., *The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci.* 11: 423, 1990), and whether the arylalkylamines would elicit a PCP-like neuronal vacuolization (Olney et al., *Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science* 244: 1360, 1989).

Example 15: Locomotor activity

The first assay simply monitors locomotor activity 35 during the first hour following peripheral (s.c. or i.p.)

WO 95/21612

PCT/US94/12293

administration of test substance. Mice received a dose of Compound 1 15 min before being placed into activity chambers. Activity was quantified by counting the number of breaks in a phototube grid in a 60 min period. In this 5 assay, MK-801 (0.25 mg/kg p.o.) causes a 2- to 3-fold increase in locomotor activity. However, Compound 1, even when tested at 32 mg/kg s.c., did not elicit hyperactivity and, in fact, tended to depress it. This result, using a purified arylalkylamine in mice, complements earlier 10 results obtained in rats where the entire arylalkylamine-containing fraction from *Agelenopsis aperta*, when injected intravenously, did not elicit a PCP-like behavioral syndrome but seemed to produce a mild sedative effect.

Example 16: Motor impairment

15 In the first assay for generalized motor impairment, Compound 1 was examined in the inverted grid assay. In this assay, animals are placed on a wire-holed grid suspended from a rotating metal bar which can be inverted. The animals are then scored for their ability to climb to 20 the top or hang on to the grid. Animals with severe motor impairment fall off the grid. This assay provides an index of "behavioral disruption" that may result from ataxia, loss of the righting reflex, sedation, or muscle relaxation. In these tests, Compound 1, administered at 25 32 mg/kg s.c., did not lessen the ability of DBA/2 mice to right themselves when the grid was inverted ($p > 0.05$). Compound 2 was likewise without effect ($p > 0.05$) on motor performance in DBA/2 mice when administered at a dose of 20 mg/kg s.c. These doses are considerably higher than 30 those required to prevent sound-induced seizures in DBA/2 mice (see Example 10 above).

The second assay of acute motor impairment was the rotarod assay. In this assay, Frings and CF1 mice were injected with test compound and placed on a knurled rod 35 which rotated at a speed of 6 rpm. The ability of the mice to maintain equilibrium for long periods of time was

WO 95/21612

PCT/US94/12293

59

determined; those mice that were unable to maintain equilibrium on the rotorod for 1 min in each of 3 trials were considered impaired. Compound 1 produced acute motor impairment in Frings mice with a TD₅₀ (that dose which 5 produced motor toxicity in 50% of the test animals) of 16.8 mg/kg i.p. This dose is similar to that which prevents sound-induced seizures in Frings mice (see Example 10 above). There is a much clearer separation between effective and toxic doses of Compound 1 in Frings 10 mice, however, when the Compound is administered i.c.v. In this case, no apparent motor toxicity was evident until the dose of Compound 1 exceeded 1.56 µg i.c.v. (>2 times the ED₅₀ of 0.63 µg). Finally, motor impairment in CF1 mice was noted with Compound 1 following i.c.v. 15 administration of 4 µg.

Compound 4, Compound 9, Compound 12 and Compound 14 were administered to Frings mice by i.c.v. injection, and acute motor impairment was measured. The TD₅₀ values for Compounds 4, 9, 12 and 14 were 8-16 µg, 14.8 µg, 30.2 µg 20 and 30.8 µg, respectively. These TD₅₀ values were 2-3 times higher than the effective IC₅₀ values for anti-convulsant potency (see Example 10 above); a clear separation between effective and toxic doses was noted.

Example 17. PCP discrimination

25 In this assay, rats who have been trained to lever press for food reinforcement must select which of two levers in their cages is correct. The only stimulus they have for selecting the correct lever is their ability to detect whether they received a PCP or vehicle injection. 30 After about two months of training, rats become very good at discriminating PCP from vehicle injections and can then be tested with other drugs to determine if they are discriminated as PCP. When tested in this procedure, other drugs which are known to produce a PCP-like intoxication 35 substitute for PCP. These drugs include various PCP

WO 95/21612

PCT/US94/12293

60

analogs such as ketamine and the noncompetitive NMDA receptor antagonist, MK-801.

Compound 1 (1 - 30 mg/kg i.p.) did not substitute for PCP, and thus was completely devoid of PCP-like discriminative stimulus effects. At 30 mg/kg i.p., only 1 of the 7 animals tested responded at all on either lever. It is thus clear that a behaviorally effective dosage range of Compound 1 was evaluated. As the ability of test compounds to produce PCP-like effects in rats is believed to be predictive of their ability to produce PCP-like psychotomimetic activity and abuse liability in humans, these results strongly suggest that the arylalkylamines such as Compound 1 will lack such deleterious side effects in man.

15 Example 18. Neuronal vacuolization.

The administration of compounds such as PCP and MK-801 to rats produces a neurotoxic effect termed neuronal vacuolization. Following a single dose of such compounds, vacuoles are found in particular central neurons, especially those in the cingulate cortex and retrosplenial cortex. No such vacuolization was present in rats treated with Compound 1 at the single high dose of 100 mg/kg i.p.

Taken together, the results on locomotor activity, motor impairment, PCP discrimination and neuronal vacuolization strongly suggest that arylalkylamines will be devoid of PCP-like side effects in man.

(b) Cognitive impairment

One of the major reasons for postulating a role of NMDA receptors in memory and learning derives from cellular studies on long-term potentiation (LTP) in the rat hippocampus. LTP is a long-lasting increase in the magnitude of synaptic responses produced by brief yet intense synaptic stimulation. Since the discovery of this phenomenon, it has become the preeminent cellular model of learning in the vertebrate brain (Teyler and Discenna,

WO 95/21612

PCT/US94/12293

61

Long-term potentiation. *Annu. Rev. Neurosci.* 10: 131, 1987). Transmission at synapses formed by Schaffer collaterals onto CA1 pyramidal cells is mediated by NMDA and AMPA receptors. Following a brief tetanizing stimulus, the magnitude of the population spike (a measure of synaptic transmission) is greatly increased and remains so for hours. It has been shown that all known competitive and noncompetitive antagonists of NMDA receptors block LTP in the rat hippocampus, whereas antagonists of non-NMDA receptors are without effect (Collingridge and Davis, In: *The NMDA Receptor*, IRL Press. p. 123, 1989). This supports a role of NMDA receptors in memory and learning.

Example 19: LTP assay

The effects of selected arylalkylamines and literature standards were examined for effects on LTP in slices of rat hippocampus. As anticipated, all the conventional competitive (AP5 and AP7) and noncompetitive (MK-801 and ifenprodil) NMDA receptor antagonists inhibited the induction of LTP in the hippocampus. Slices of rat hippocampus were superfused for 30-60 min with a test compound before delivering a tetanizing stimulus consisting of 3 trains, separated by 500 msec, of 100 Hz for 1 sec each. The response amplitude was monitored for an additional 15 minutes post-tetanus. The tetanizing stimulus caused a mean 95% increase in the amplitude of the synaptic response. The induction of LTP was significantly blocked ($p < 0.05$) by competitive (AP5, AP7) or noncompetitive (MK-801, ifenprodil) NMDA receptor antagonists. Quite surprisingly, none of the arylalkylamines tested (Compound 1, Compound 2, Compound 3 and others) blocked the induction of LTP ($p > 0.05$), even when used at high concentrations (100-300 μ M) that caused some inhibition of the control response.

These results highlight yet another unique and important feature of arylalkylamines. Arylalkylamines are the first, and at present the only, class of compounds

WO 95/21612

PCT/US94/12293

62

shown to be selective and potent antagonists of the NMDA receptor that do not block the induction of LTP. This likely reflects the novel mechanism and site of action of arylalkylamines and suggests that drugs which target the 5 novel site on the NMDA receptor will similarly lack effects on LTP. As LTP is the primary cellular model for learning and memory in the mammalian CNS, it additionally suggests that such drugs will lack deleterious effects on cognitive performance.

10 Example 20: Learning tests

Preliminary experiments using one of the more potent synthetic arylalkylamine analogs, Compound 3, in an *in vivo* learning paradigm demonstrate that these drugs lack effects on cognitive performance. In this test, rats were 15 trained to alternate turning in a T maze for a food reward. MK-801 was included for comparison. Test compounds were administered i.p. 15 min before testing. Control animals made the correct choice about 80% of the time. Increasing doses of MK-801 progressively decreased 20 the number of correct choices and this decrement in behavior was accompanied by hyperactivity. In contrast, Compound 3 did not impair the ability of the animals to make the correct choices ($p > 0.05$). At the highest doses tested, Compound 3 caused some decrease in locomotor 25 activity, exactly the opposite effect observed with MK-801.

Although MK-801 decreased learning performance in parallel with increases in locomotor activity, other studies using different paradigms in rodents and primates 30 have shown a clear dissociation between the effects on learning and locomotion. Thus, both competitive and noncompetitive NMDA receptor antagonists impair learning at doses which do not cause any overt change in motor behavior. This demonstrates that conventional NMDA 35 receptor antagonists impair learning independently of other side effects. The results of the T-maze assay

WO 95/21612

PCT/US94/12293

63

demonstrate that Compound 3, and other arylalkylamines, do not impair learning even at doses that cause some decrease in locomotor activity.

One additional observation emerged from these 5 learning tests. The animals' first response on the second day of testing was random and was therefore not dependent on the last response of the previous day's testing. Control animals thus correctly made the first choice about 50% of the time. MK-801 has no effect on this first 10 choice. However, animals administered Compound 3 on the previous day made the first choice correctly considerably more often. Unlike control animals then, the animals treated with Compound 3 behaved as if they remembered the last choice of the previous day.

15 In a second series of experiments, the effect of Compound 4 on learning in the Morris water maze task was evaluated. In this test, a hidden platform was placed in a fixed location in a circular steel tank, and submerged 2 cm below the surface of the water. Each rat was given 20 3 trials per day with a 10 min intertrial interval for 5 days. A trial was initiated by placing the rat in the water, nose facing the wall of the tank, at one of three predetermined starting locations. The order of the start location was varied daily. Learning was measured as a 25 decrease in time required to swim to the platform. If an animal failed to locate the platform within 60 sec after the start of the trial, the rat was hand-guided to it. The animals remained on the platform for 10 sec before being removed from the tank. Ten min after the last 30 training trial on day 5, the animals received a probe test. The platform was removed for this 1 trial task and the animals were allowed to swim for 60 sec to assess the spatial bias for the platform location. Two measures were recorded from this task: latency to first crossing the 35 area where the platform had been, and total number of crossings. A total of 5 injections of Compound 4 were given to each rat. In the first series of experiments,

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

64

Compound 4 was administered at 10 mg/kg i.p. daily for 5 days. This treatment regimen impaired learning; however, these animals experienced significant weight loss and unusual behavioral signs ("shivering," motor impairment, 5 difficulty in swimming) with repeated dosing of Compound 4. In a subsequent study, six animals received 1 mg/kg i.p. for the first 4 days of training, while two animals received 5 mg/kg i.p. during this period. On the last day of training, both groups received 10 mg/kg. Neither the 10 1 mg/kg nor the 5 mg/kg animals showed any impairment in learning the location of the hidden platform, nor did the final 10 mg/kg dose produce any impairment in the ability of the animal to perform the already learned task.

The results of these learning tasks are encouraging. 15 They suggest that arylalkylamines lack the learning and memory deficits that typify other NMDA receptor antagonists. In fact, there is a suggestion that the arylalkylamines may even be nootropic (memory enhancers).

(c) Cardiovascular effects

20 In vivo studies with certain arylalkylamines revealed a hypotensive effect of these compounds, especially at high doses. On the basis of these results, a systematic study of the effects of arylalkylamines on cardiovascular function was performed.

25 Example 21: Ca²⁺ channel inhibition

We have discovered that some of the arylalkylamines are quite potent inhibitors of voltage-sensitive Ca²⁺ channels, specifically those sensitive to inhibition by dihydropyridines (L-type channels). Such effects on 30 vascular smooth muscle would be expected to dilate blood vessels and cause a drop in blood pressure, thus producing hypotension.

The ability of arylalkylamines to inhibit dihydropyridine-sensitive Ca²⁺ channels was examined in 35 cerebellar granule cells and a rat aortic smooth muscle

WO 95/21612

PCT/US94/12293

65

cell line, A₇r5 cells. In cerebellar granule cells, Compound 2 inhibited depolarization-induced increases in [Ca²⁺]_i at concentrations 100-fold higher than those required to block responses to NMDA (IC₅₀ values of 24 μM and 161 nM, respectively). Overall, we have observed a wide range of potencies against voltage-sensitive Ca²⁺ channels that does not correlate with potency against NMDA receptors. This strongly suggests that further structure-activity work based on chemical modification of the arylalkylamine molecule will lead to the development of compounds that are very potent NMDA antagonists with low potency against voltage-sensitive Ca²⁺ channels. Indeed, Compound 1 (with an IC₅₀ of 102 nM against NMDA receptor-mediated responses in cerebellar granule cells) is a relatively poor inhibitor of voltage-sensitive Ca²⁺ channels in cerebellar granule cells (IC₅₀ = 257 μM) and is virtually without effect on voltage-sensitive Ca²⁺ influx in A₇r5 cells (IC₅₀ = 808 μM).

Arylalkylamines are not, however, indiscriminate blockers of voltage-sensitive Ca²⁺ channels. They do not, for example, affect voltage-sensitive Ca²⁺ channels in cerebellar Purkinje cells (P-type channels) or those channels thought to be involved in neurotransmitter release (N-channels). The arylalkylamines that do block voltage-sensitive Ca²⁺ channels appear to target specifically L-type Ca²⁺ channels. Moreover, as mentioned above, there is a high degree of structural specificity in this effect. For example, one arylalkylamine is 57 times more potent than another arylalkylamine in blocking Ca²⁺ influx through L-type channels, where the only structural difference between the compounds is the presence or absence of a hydroxyl group.

Example 22: *In vivo* cardiovascular studies

The arylalkylamines Compound 1 and Compound 2 produce moderate drops (20-40 mm Hg) in mean arterial blood pressure (MAPB) in anesthetized rats at doses which are

WO 95/21612

PCT/US94/12293

effective in the *in vivo* stroke models (10-30 mg/kg s.c.). The hypotensive effect of Compound 4 has been evaluated in greater detail. Compound 4 elicited a marked drop (40 mm Hg) in mean arterial pressure which persisted for approximately 90-120 min when administered at the dose of 10 mg/kg i.p.; it was in this same group of rats that Compound 4 afforded significant neuroprotection in the suture model of middle cerebral artery occlusion (see Example 8 above). Similar results were obtained in the rat study in which Compound 4 demonstrated neuroprotectant activity in the Rose Bengal photothrombotic model of focal ischemic stroke (see Example 8 above). Further studies using the pithed rat preparation strongly suggest that the hypotensive activity of Compound 4 is a peripherally mediated effect. The hypotension and bradycardia produced by Compound 4 was maintained in rats pretreated with atropine, suggesting that these effects are not mediated by a cholinergic mechanism. Similarly, Compound 4 elicited hypotension and bradycardia in chemically sympathectomized rats (pretreated with a ganglionic blocker), suggesting that these effects are not mediated via the sympathetic nervous system.

On the basis of these findings, it is anticipated that chemical efforts will minimize the cardiovascular side effects by (1) enhancing the uptake of arylalkylamine into the brain such that lower doses are required for neuroprotection, and (2) increasing the selectivity (potency ratio) of arylalkylamines for receptor-operated Ca^{2+} channels over voltage-sensitive Ca^{2+} channels.


30 Chemistry and biological activity of simplified synthetic arylalkylamines

Simplified arylalkylamines comprise the following structures:


WO 95/21612

PCT/US94/12293



67





where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl or O-acyl, and each R² can be, independently, H or lower alkyl; or



- 5 where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl; or



- where n = 1-6, and each X can be, independently, one or
10 more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and R² can be H or lower alkyl; or



SUBSTITUTE SHEET (RULE 26)

WO 95/21612


PCT/US94/12293

68


where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl.

- 5 These compounds are potentially useful in the present invention in place of the more complex Compounds 1, 2 and 3 above.


Examples of such simplified arylalkylamines include, but are not limited to, Compounds 19 through 53, whose
10 structures are provided below.




Compound 19



Compound 20



Compound 21




Compound 22

SUBSTITUTE SHEET (RULE 26)


WO 95/21612

PCT/US94/12293


69




Compound 23




Compound 24



Compound 25



Compound 26




Compound 27


WO 95/21612

PCT/US94/12293


70




Compound 28




Compound 29



Compound 30



Compound 31




Compound 32


WO 95/21612

PCT/US94/12293


71




Compound 33




Compound 34




Compound 35



Compound 36



Compound 37




Compound 38


WO 95/21612

PCT/US94/12293

72



Compound 39



Compound 40




Compound 41



Compound 42



Compound 43




Compound 44


WO 95/21612

PCT/US94/12293


73




Compound 45




Compound 46



Compound 47



Compound 48



Compound 49



Compound 50

WO 95/21612

PCT/US94/12293


74



Compound 51



Compound 52



Compound 53

Example 23: Biological activity of Compound 19 and analogs

Compounds 19 - 53 had high potencies against NMDA-induced increases in $[Ca^{2+}]_i$ in rat cerebellar granule cells grown in culture (Table 1). The inhibitory effect
 5 of Compound 19 on responses to NMDA was noncompetitive. Compounds 19- 37 inhibited $[^3H]MK-801$ binding in membranes prepared from rat hippocampal and cortical tissue (Table 1).

Compound 19 possessed the following additional
 10 biological activities: significant ($p < 0.05$ compared to control) anticonvulsant activity against maximal electroshock-induced seizures in mice following i.p. administration ($ED_{50} = 26.4$ mg/kg and TD_{50} (rotorod) = 43.8 mg/kg); significant anticonvulsant activity against
 15 maximal electroshock-induced seizures in mice following oral (p.o.) administration ($ED_{50} = 35$ mg/kg), but with motor impairment at 30 mg/kg; significant analgesic activity in the hot-plate and PBQ-induced writhing assays

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

at 16 mg/kg i.p.; no PCP-like stereotypic behavior (hyperexcitability and head weaving) at 30 mg/kg i.p. in rats; no generalization to PCP in the PCP discrimination assay at doses up to the behaviorally active dose of 30
5 mg/kg i.p. Compound 19 was significantly less potent in antagonizing increases in $[Ca^{2+}]_i$ elicited by depolarizing concentrations of KCl in rat cerebellar granule cells ($IC_{50} = 10.2 \mu M$), and was without effect on blood pressure when administered s.c. in rats at doses up to 100 mg/kg.
10 Compound 19, however, did block the induction of LTP in rat hippocampal slices when tested at 100 μM .

Compound 20 possessed the following additional biological activities: significant anticonvulsant activity against maximal electroshock-induced seizures in mice
15 following i.p. administration ($ED_{50} = 20.1 \text{ mg/kg}$ and $TD_{50} (\text{rotorod}) = 20.6 \text{ mg/kg}$); no significant anticonvulsant activity against maximal electroshock-induced seizures in mice following oral (p.o.) administration at doses up to 30 mg/kg, but with motor impairment at 30 mg/kg; significant
20 anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. ($ED_{50} = 2.1 \text{ mg/kg}$ and $TD_{50} = 19.9 \text{ mg/kg}$) and oral ($ED_{50} = 9.7 \text{ mg/kg}$ and $TD_{50} = 21.8 \text{ mg/kg}$) administration; significant neuroprotective activity in the rat model of temporary focal ischemia (a 51% reduction in the infarct volume following the administration of two doses of 1 mg/kg i.p., the first given immediately after middle cerebral artery occlusion and the second given 6 hr later; a 43% reduction in the
25 infarct volume following the administration of two doses of 1 mg/kg i.p., the first given 2 hr after middle cerebral artery occlusion (i.e., at the time of reperfusion) and the second given 6 hr later); no generalization to PCP in the PCP discrimination assay at doses up to the
30 behaviorally active dose of 10 mg/kg i.p.; no neuronal vacuolization when administered at doses of 10 and 30
35

WO 95/21612

PCT/US94/12293

mg/kg i.p.; and no significant cardiovascular activity at doses up to 15 μ moles/kg i.v. or 10 mg/kg i.p.

Compound 21 possessed the following additional biological activities: significant anticonvulsant 5 activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. administration (ED_{50} = 3.41 mg/kg and TD_{50} (tremors) = 15.3 mg/kg).

Compound 22 possessed the following additional 10 biological activities: significant anticonvulsant activity against sound-induced seizures in a genetically susceptible mouse model of reflex epilepsy (Frings mice) following i.p. (ED_{50} = 4.90 mg/kg and TD_{50} (inverted grid) = 26.8 mg/kg) and oral (ED_{50} = 5.1 mg/kg and LD_{50} = 18.3 15 mg/kg) administration; and no significant cardiovascular activity at doses below 15 μ moles/kg (4.47 mg/kg) i.v.

Taken together, the results obtained with these simplified synthetic arylalkylamines suggest that such simplified molecules do not interact specifically with the 20 arylalkylamine binding site on receptor-operated Ca^{2+} channels as do Compounds 1, 2 and 3. Specifically, Compounds 19 - 53 bind to the site labeled by [3H]MK-801 at concentrations ranging approximately 1 to 50-fold higher than those which antagonize the function of the 25 NMDA receptor-ionophore complex. The fact that Compounds 19 - 53 at therapeutic doses do not produce PCP-like stereotypic behavior, substitute for PCP in drug discrimination assays, or elicit neuronal vacuolization suggests, however, that such compounds might be useful 30 either as lead compounds or drug candidates for neurological disorders and diseases. It has been reported that compounds which bind with low affinity (relative to MK-801) to the site labeled by [3H]MK-801 might possess therapeutic utility and possess a more favorable side 35 effect profile than that possessed by a high affinity antagonist such as MK-801 itself (Rogawski, Therapeutic potential of excitatory amino acid antagonists: channel

WO 95/21612

PCT/US94/12293

blockers and 2,3-benzodiazepines. *Trends Pharmacol. Sci.* 14: 325, 1993). The low affinity of Compounds 19 - 53 (relative to MK-801) for the site labeled by [³H]MK-801 places Compounds 19 - 53 into this general class of low 5 affinity noncompetitive antagonists.

Identification of a novel modulatory site on receptor-operated calcium channels

Having identified arylalkylamines which have therapeutically useful properties as defined above, 10 compounds can now be identified which act at the critical arylalkylamine binding site on receptor-operated Ca²⁺ channels, such as those present within NMDA, AMPA and nicotinic cholinergic receptor-ionophore complexes.

Examples of suitable tests now follow:

15 Example 24: Radioligand binding in rat cortex or cerebellum.

The following assay can be utilized as a high throughput assay to screen product libraries (e.g., natural product libraries and compound files at major 20 pharmaceutical companies) to identify new classes of compounds with activity at this unique arylalkylamine site. These new classes of compounds are then utilized as chemical lead structures for a drug development program targeting the arylalkylamine binding site on receptor-operated Ca²⁺ channels. The compounds identified by this 25 assay offer a novel therapeutic approach to treatment of neurological disorders or diseases. Examples of such compounds include those provided in the generic chemical formulae above. Routine experiments can be performed to 30 identify those compounds having the desired activities.

Rat brain membranes are prepared according to the method of Williams et al. (Effects of polyamines on the binding of [³H]MK-801 to the NMDA receptor: Pharmacological evidence for the existence of a polyamine recognition 35 site. *Molec. Pharmacol.* 36: 575, 1989) with the following

WO 95/21612

PCT/US94/12293

alterations: Male Sprague-Dawley rats (Harlan Laboratories) weighing 100-200 g are sacrificed by decapitation. The cortex or cerebellum from 20 rats are cleaned and dissected. The resulting brain tissue is homogenized at 5 4°C with a polytron homogenizer at the lowest setting in 300 ml 0.32 M sucrose containing 5 mM K-EDTA (pH 7.0). The homogenate is centrifuged for 10 min at 1,000 x g and the supernatant removed and centrifuged at 30,000 x g for 30 minutes. The resulting pellet is resuspended in 250 ml 10 5 mM K-EDTA (pH 7.0) stirred on ice for 15 min, and then centrifuged at 30,000 x g for 30 minutes. The pellet is resuspended in 300 ml 5 mM K-EDTA (pH 7.0) and incubated at 32°C for 30 min. The suspension is then centrifuged at 100,000 x g for 30 min. Membranes are washed by resus- 15 pension in 500 ml 5 mM K-EDTA (pH 7.0), incubated at 32°C for 30 min, and centrifuged at 100,000 x g for 30 minutes. The wash procedure, including the 30 min incubation, is repeated. The final pellet is resuspended in 60 ml 5 mM K-EDTA (pH 7.0) and stored in aliquots at -80°C. The 20 extensive washing procedure utilized in this assay was designed in an effort to minimize the concentrations of glutamate and glycine (co-agonists at the NMDA receptor-ionophore complex) present in the membrane preparation.

To perform a binding assay with [³H]arylalkylamine, 25 aliquots of SPMs (Synaptic Plasma Membranes) are thawed, resuspended in 30 mls of 30 mM EPPS/1mM K-EDTA, pH 7.0, and centrifuged at 100,000 x g for 30 minutes. SPMs are resuspended in buffer A (30 mM EPPS/1 mM K-EDTA, pH 7.0). The [³H]arylalkylamine is added to this reaction mixture. 30 Binding assays are carried out in polypropylene test tubes. The final incubation volume is 500 µl. Nonspecific binding is determined in the presence of 100 µM nonradioactive arylalkylamine. Duplicate samples are incubated at 0°C for 1 hour. Assays are terminated by the 35 addition of 3 ml of ice-cold buffer A, followed by filtration over glass-fiber filters (Schleicher & Schuell No. 30) that are presoaked in 0.33% polyethyleneimine

WO 95/21612

PCT/US94/12293

(PEI). The filters are washed with another 3 x 3 ml of buffer A, and radioactivity is determined by scintillation counting at an efficiency of 35-40% for ^3H .

In order to validate the above assay, the following 5 experiments are also performed:

(a) The amount of nonspecific binding of the $[^3\text{H}]$ arylalkylamine to the filters is determined by passing 500 μl of buffer A containing various concentrations of $[^3\text{H}]$ arylalkylamine through the presoaked glass-fiber 10 filters. The filters are washed with another 4 x 3 ml of buffer A, and radioactivity bound to the filters is determined by scintillation counting at an efficiency of 35-40% for ^3H . In filters that are not pretreated with 0.33% PEI, it was found that 87% of the ^3H -ligand was bound 15 to the filter. Presoaking with 0.33% PEI reduces the nonspecific binding to 0.5 - 1.0% of the total ligand added.

(b) A saturation curve is constructed by resuspending SPMs in buffer A. The assay buffer (500 μl) contains 60 20 μg of protein. Concentrations of $[^3\text{H}]$ arylalkylamine are used, ranging from 1.0 nM to 400 μM in half-log units. A saturation curve is constructed from the data, and an apparent K_D value and B_{\max} value determined by Scatchard analysis (Scatchard, The attractions of proteins for small 25 molecules and ions. *Ann. N.Y. Acad. Sci.* 51: 660, 1949). The cooperativity of binding of the $[^3\text{H}]$ arylalkylamine is determined by the construction of a Hill plot (Hill, A new mathematical treatment of changes of ionic concentrations in muscle and nerve under the action of electric currents, 30 with a theory to their mode of excitation. *J. Physiol.* 40: 190, 1910).

(c) The dependence of binding on protein (receptor) concentration is determined by resuspending SPMs in buffer A. The assay buffer (500 μl) contains a concentration of 35 $[^3\text{H}]$ arylalkylamine equal to its K_D value and increasing concentrations of protein. The specific binding of

WO 95/21612

PCT/US94/12293

80

[³H]arylalkylamine should be linearly related to the amount of protein (receptor) present.

(d) The time course of ligand-receptor binding is determined by resuspending SPMs in buffer A. The assay 5 buffer (500 μ l) contains a concentration of [³H]arylalkylamine equal to its K_D value and 100 μ g of protein. Duplicate samples are incubated at 0°C for varying lengths of time; the time at which equilibrium is reached is determined, and this time point is routinely used in all 10 subsequent assays.

(e) The pharmacology of the binding site can be analyzed by competition experiments. In such experiments, the concentration of [³H]arylalkylamine and the amount of protein are kept constant, while the concentration of test 15 (competing) drug is varied. This assay allows for the determination of an IC_{50} and an apparent K_D for the competing drug (Cheng and Prusoff, Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (IC_{50}) of an 20 enzymatic reaction. *J. Biochem. Pharmacol.* 22: 3099, 1973). The cooperativity of binding of the competing drug is determined by Hill plot analysis.

Specific binding of the [³H]arylalkylamine represents binding to a novel site on receptor-operated Ca^{2+} channels 25 such as those present within NMDA-, AMPA- and nicotinic cholinergic receptor-ionophore complexes. As such, other arylalkylamines should compete with the binding of [³H]arylalkylamine in a competitive fashion, and their potencies in this assay should correlate with their 30 inhibitory potencies in a functional assay of receptor-operated Ca^{2+} channel antagonism (e.g., inhibition of NMDA receptor-induced increases in $[Ca^{2+}]_i$ in cultures of rat cerebellar granule cells). Conversely, compounds which have activity at the other known sites on receptor-operated Ca^{2+} channels (e.g., MK-801, Mg^{2+} , polyamines) 35 should not displace [³H]arylalkylamine binding in a competitive manner. Rather, complex allosteric modulation

WO 95/21612

PCT/US94/12293

81

of [³H]arylalkylamine binding, indicative of noncompetitive interactions, might be expected to occur. In preliminary experiments, MK-801 did not displace [³H]arylalkylamine binding at concentrations up to 100 μ M.

5 (f) Studies to estimate the dissociation kinetics are performed by measuring the binding of [³H]arylalkylamine after it is allowed to come to equilibrium (see (d) above), and a large excess of nonradioactive competing drug is added to the reaction mixture. Binding of the
10 [³H]arylalkylamine is then assayed at various time intervals. With this assay, the association and dissociation rates of binding of the [³H]arylalkylamine are determined (Titeler, *Multiple Dopamine Receptors: Receptor Binding Studies in Dopamine Pharmacology*. Marcel Dekker, Inc.,
15 New York, 1983). Additional experiments involve varying the reaction temperature (0°C to 37°C) in order to understand the temperature dependence of this parameter.

Example 25: Radioligand binding in cerebellar granule cells

20 Primary cultures of cerebellar granule neurons are obtained from 8-day-old rats and plated onto squares of Aclar plastic coated with poly-L-lysine. The plastic squares are placed in 24-well culture plates, and approximately 7.5×10^5 granule cells are added to each well.
25 Cultures are maintained in Eagles' medium (HyClone Laboratories) containing 25 mM KCl, 10% fetal calf serum (HyClone Laboratories), 2 mM glutamine, 100 μ g/ml gentamicin, 50 U/ml penicillin, and 50 μ g/ml streptomycin at 37°C in a humid atmosphere of 5% CO₂ in air for 24 h before
30 the addition of cytosine arabinoside (10 μ M, final). No changes of culture medium are made until the cells are used for receptor binding studies 6-8 days after plating.

To perform a binding assay with [³H]arylalkylamine, the reaction mixture consists of 200 μ l of buffer A (20 mM
35 K-HEPES, 1 mM K-EDTA, pH 7.0) in each well of the 24-well plate. The [³H]arylalkylamine is added to this reaction

WO 95/21612

PCT/US94/12293

82

mixture. Nonspecific binding is determined in the presence of 100 μ M nonradioactive arylalkylamine. Triplicate samples are incubated at 0°C for 1 hour. Assays are terminated by manually scraping the cells off the Aclar squares and placing them into polypropylene test tubes. The membranes prepared from whole cells in this manner are suspended in 10 ml of ice-cold buffer A, and filtered over glass-fiber filters (Schleicher & Schuell No. 30) that are presoaked in 0.33% PEI. The filters are washed with another 3 x 3 ml of buffer A, and radioactivity on the filters is determined by scintillation counting at an efficiency of 35-40% for 3 H. The assay may be terminated by centrifugation rather than filtration in order to minimize nonspecific binding.

Specific experiments to characterize and validate the assay are performed essentially as above, except that cells are used in place of membranes for the initial binding. The binding assay allows for the determination of an IC₅₀ value and an apparent K_D for the competing drug as described by Scatchard analysis (The attractions of proteins for small molecules and ions. *Ann. N.Y. Acad. Sci.* 51: 660, 1949). Cooperativity of binding of the competing drug is determined by Hill plot analysis (A new mathematical treatment of changes of ionic concentrations in muscle and nerve under the action of electric currents, with a theory to their mode of excitation. *J. Physiol.* 40: 190, 1910). The specific binding of the [3 H]arylalkylamine represents binding to a novel site on receptor-operated calcium channels.

30 Example 26: Recombinant receptor binding assay

The following is one example of a rapid screening assay for useful compounds of this invention. In this assay, a cDNA or gene clone encoding the arylalkylamine binding site (receptor) from a suitable organism such as a human is obtained using standard procedures. Distinct fragments of the clone are expressed in an appropriate

WO 95/21612

PCT/US94/12293

expression vector to produce the smallest polypeptide(s) obtainable from the receptor which retain the ability to bind Compound 1, Compound 2 or Compound 3. In this way, the polypeptide(s) which includes the novel arylalkylamine receptor for these compounds can be identified. Such experiments can be facilitated by utilizing a stably transfected mammalian cell line (e.g., HEK 293 cells) expressing the arylalkylamine receptor.

Alternatively, the arylalkylamine receptor can be chemically reacted with chemically modified Compound 1, Compound 2 or Compound 3 in such a way that amino acid residues of the arylalkylamine receptor which contact (or are adjacent to) the selected compound are modified and thereby identifiable. The fragment(s) of the arylalkylamine receptor containing those amino acids which are determined to interact with Compound 1, Compound 2 or Compound 3 and are sufficient for binding to said molecules, can then be recombinantly expressed, as described above, using a standard expression vector(s).

The recombinant polypeptide(s) having the desired binding properties can be bound to a solid phase support using standard chemical procedures. This solid phase, or affinity matrix, may then be contacted with Compound 1, Compound 2 or Compound 3 to demonstrate that those compounds can bind to the column, and to identify conditions by which the compounds may be removed from the solid phase. This procedure may then be repeated using a large library of compounds to determine those compounds which are able to bind to the affinity matrix, and then can be released in a manner similar to Compound 1, Compound 2 or Compound 3. However, alternative binding and release conditions may be utilized in order to obtain compounds capable of binding under conditions distinct from those used for arylalkylamine binding (e.g., conditions which better mimic physiological conditions encountered especially in pathological states). Those compounds which do

WO 95/21612

PCT/US94/12293

bind can thus be selected from a very large collection of compounds present in a liquid medium or extract.

Once compounds able to bind to the arylalkylamine binding polypeptide(s) described above are identified, 5 those compounds can then be readily tested in the various assays described above to determine whether they, or simple derivatives thereof, are useful compounds for therapeutic treatment of neurological disorders and diseases described above.

10 In an alternate method, native arylalkylamine receptor can be bound to a column or other solid phase support. Those compounds which are not competed off by reagents which bind other sites on the receptor can then be identified. Such compounds define novel binding sites 15 on the receptor. Compounds which are competed off by other known compounds thus bind to known sites, or bind to novel sites which overlap known binding sites. Regardless, such compounds may be structurally distinct from known compounds and thus may define novel chemical 20 classes of agonists or antagonist which may be useful as therapeutics. In summary, a competition assay can be used to identify useful compounds of this invention.

Example 27: Patch-clamp electrophysiology assay

The following assay is performed for selected 25 compounds identified in the above-mentioned radioligand binding assays as interacting in a highly potent and competitive fashion at the novel arylalkylamine binding site on receptor-operated Ca^{2+} channels, such as those present in NMDA-, AMPA- or nicotinic cholinergic receptor- 30 ionophore complexes. This patch-clamp assay provides additional relevant data about the site and mechanism of action of said previously selected compounds. Specifically, the following pharmacological and physiological properties of the compounds interacting at the arylalkyl- 35 amine binding site are determined, utilizing the NMDA receptor-ionophore complex as an example of receptor-

WO 95/21612

PCT/US94/12293

85

operated Ca^{2+} channels: potency and efficacy at blocking NMDA receptor-mediated ionic currents, the noncompetitive nature of block with respect to glutamate and glycine, use-dependence of action, voltage-dependence of action, 5 both with respect to onset and reversal of blocking, the kinetics of blocking and unblocking (reversal), and open-channel mechanism of blocking. Such data confirm that the compounds interacting at the arylalkylamine binding site retain the unique biological profile of the arylalkyl-10 amines, and do not have their primary activity at the known sites on the NMDA receptor-ionophore complex (glutamate binding site, glycine binding site, MK-801 binding site, Mg^{2+} binding site, Zn^{2+} binding site, sigma binding site, polyamine binding site).

15 Patch-clamp recordings of mammalian neurons (hippocampal, cortical, cerebellar granule cells) are carried out utilizing standard procedures (Donevan et al., Arcaine blocks N-methyl-D-aspartate receptor responses by an open channel mechanism: whole-cell and single-channel recording 20 studies in cultured hippocampal neurons. Molec. Pharmacol. 41: 727, 1992; Rock and Macdonald, Spermine and related polyamines produce a voltage-dependent reduction of NMDA receptor single-channel conductance. Molec. Pharmacol. 42: 157, 1992).

25 Alternatively, patch-clamp experiments can be performed on *Xenopus* oocytes or on a stably transfected mammalian cell line (e.g., HEK 293 cells) expressing specific subunits of receptor-operated Ca^{2+} channels. In this manner, for example, potency and efficacy at various 30 glutamate receptor subtypes (e.g., NMDAR1, NMDAR2A through NMDAR2D, GluR1 through GluR4) can be determined. Further information regarding the site of action of the arylalkylamines on these glutamate receptor subtypes can be obtained by using site-directed mutagenesis.

WO 95/21612

PCT/US94/12293

Example 28: Synthesis of arylalkylamines

Arylalkylamines such as Compound 1, Compound 2 and Compound 3 are synthesized by standard procedures (Jasys et al., The total synthesis of argiotoxins 636, 659 and 5 673. *Tetrahedron Lett.* 29: 6223, 1988; Nason et al., Synthesis of neurotoxic *Nephila* spider venoms: NSTX-3 and JSTX-3. *Tetrahedron Lett.* 30: 2337, 1989). Specific examples of syntheses of arylalkylamine analogs are provided below.

10 Synthesis of Compound 4 was accomplished as follows:

A solution of 1,4-diaminobutane (203.4 g, 2.312 mol) in methanol (50 mL) was treated with acrylonitrile (AN, 135 g, 2.543 mol) at a rate of 40 mL/h. The reaction was stirred 16 hr at room temperature (20-25°C). GC-MS showed 15 64% of the product A; GC-MS ($R_t = 4.26$ min) m/z (relative intensity) 141 (M^+ , 4), 124 (8), 101 (42), 83 (100), 70 (65), 56 (63), 42 (81), and 36% of the di-addition product B; GC-MS ($R_t = 7.50$ min) m/z (relative intensity) 194 (M^+ , 13), 154 (23), 123 (45), 96 (15), 83 (100), 70 (24), 56 20 (29), 42 (40). Kugelrohr distillation afforded 120 g (37%) of the product A, as a clear oil.

A solution of 3-bromo-1-propylamine hydrobromide (102.4 g, 468 mmol) and di-tert-butyldicarbonate (100.1 g, 462 mmol) in DMF (600 mL) was treated with triethylamine 25 (70 mL, 500 mmol) and the reaction stirred 1 hr at room temperature. The reaction was transferred to a separatory funnel containing 500 mL H_2O and 500 mL diethyl ether. The mixture was equilibrated and the aqueous layer removed. The ether layer was washed with 1% HCl (3x), dried over 30 K_2CO_3 and reduced to afford 105 g (95%) of the product C.

A solution of A (80 g, 567 mmol) and KF-Celite (137 g, 50 wt % on Celite) in acetonitrile (1 L) was treated with the bromide C (105 g, 444 mmol) in acetonitrile (100 mL) over 1 hr. The reaction was then stirred at 50°C for 35 24 hr. GC-MS showed that the bromide C had been consumed. The reaction was cooled, filtered and concentrated to a oil. This material was dissolved in ether (500 mL) and

WO 95/21612

PCT/US94/12293

equilibrated with water (500 mL). The ether layer was removed and the aqueous phase washed with ether (4 x 500 mL) and once with ether-dichloromethane (1:1, 500 mL). This procedure separated unreacted nitrile A (aqueous 5 fraction) from the product D. The organic washes were combined and concentrated to afford 120 g of an oil. This material was applied to a silica column (1500 cm³ of dry silica) in hexane-dichloromethane (1:1) and washed (300 mL/min) with a complex gradient of hexane-dichloromethane 10 (1:1) to dichloromethane to methanol-dichloromethane (1:9) to methanol-dichloromethane-isopropylamine (10:90:1). Like fractions (TLC analysis) were combined and concentrated to afford 93 g (70% from the bromide C) of the product D. ¹³C-NMR (CDCl₃) gave d 155.8, 118.5, 77.7, 49.3, 15 48.6, 47.3, 44.7, 38.7, 29.6, 28.1, 27.4, 27.3, 18.3, which were consistent with literature values.

A solution of D (93 g, 312 mmol) in dichloromethane (200 mL) was treated with di-tert-butyldicarbonate (80 g, 367 mmol) at a rate which gave a vigorous reflux. The 20 reaction was stirred 16 hr at room temperature and adsorbed onto 300 cm³ of silica. This was concentrated to dryness, *in vacuo*, and applied to the top of a silica column (10 cm i.d. containing 1000 cm³ dry silica). The column was washed with a gradient of hexane to ethyl 25 acetate-hexane (3:2). Like fractions were combined and concentrated to afford 89 g (49%) of the product E.

A solution of E (89 g, 179 mmol) and palladium dihydroxide (20 g) in acetic acid (300 mL) was hydrogenated at 55 p.s.i. hydrogen for 2 hr at room temperature. The reaction was filtered and concentrated to a thick oil. This material was dissolved in dichloromethane and treated with 1 N NaOH until the pH of the equilibrated 30 phases was basic (pH 14). The dichloromethane was removed and the aqueous layer washed an additional three times with dichloromethane. The organic washes were combined, dried, and concentrated to an oil. Chromatography 35 (silica) using a gradient of dichloromethane to methanol-

WO 95/21612

PCT/US94/12293

88

dichloromethane-isopropylamine (10:90:1) afforded 55 g (61%) of the product F.

Chain extension was repeated as above. A solution of F (55 g, 110 mmol) in methanol was treated with acrylonitrile (6.1 g, 116 mmol) and stirred at room temperature until the reaction was complete, as indicated by TLC analysis. The reaction was concentrated, dissolved in dichloromethane and treated with di-tert-butyl dicarbonate (26.4 g, 121 mmol). The reaction was stirred at room temperature until complete and the product purified by chromatography (silica) with a gradient of hexane to ethyl acetate-hexane (3:2). This afforded 32 g (49%) of pure G and 23 g of semi-pure material (containing primarily G). A solution of G (32 g, 49 mmol) and palladium dihydroxide (32 g) in acetic acid (300 mL) was hydrogenated at 55 p.s.i. hydrogen for 2 hr at room temperature. The reaction was processed in the same fashion as for the reaction yielding F. This afforded 24 g (33% from F) of the product H. Chain extension was repeated, as above, to afford 21 g (70%) of the polyamine I.

A solution of 5-fluoroindole-3-acetic acid (2 g, 10.4 mmol) and *p*-nitrophenol (1.6 g, 11.6 mmol) in dichloromethane (250 mL) was treated with DCC (2.4 g, 11.6 mmol) and the reaction stirred 24 hr at room temperature. The reaction mixture was filtered directly into a stirred solution of the polyamine I (21 g, 25 mmol) in dichloromethane. The reaction was stirred 4 hr at room temperature and chromatographed (silica) using a gradient of dichloromethane to methanol-dichloromethane-isopropylamine (50:950:1) to afford 8.7 g (85% from the starting indole) of the product J.


A solution of J (8.7 g, 8.8 mmol) in acetonitrile (1.8 L) was treated with concentrated HCl (200 mL) and the reaction stirred under argon for 4 hr at room temperature. The reaction was filtered and the precipitate collected to afford 5.53 g (93%) of Compound 4. The material was found

WO 95/21612

PCT/US94/12293

89

to be 98.7% pure by analytical RP-HPLC. UV_{max} (0.1% TFA) 284 nm (ϵ 6140).



Synthesis of Compound 5 was accomplished as follows. Compound 6, 7, 8 and 10 were prepared in an analogous manner except as described below.

To a solution of diaminopentane (49 g, 0.48 moles) and triethylamine (48 g, 0.43 moles) in 200 mL of dioxane was added a solution of di-tert-butyl dicarbonate (53.4 g, 0.24 moles in 200 mL of dichloromethane) over a period of 10 minutes. The reaction was stirred for another 2 hours, followed by removal of the solvents in vacuo. The result-

WO 95/21612

PCT/US94/12293

90

ing solid was taken up in ether, washed 3 x with 50 mM sodium hydroxide, 1 x with brine, dried over sodium sulfate and concentrated in vacuo. The resulting oil was dissolved in 20% ethyl acetate/hexane and applied to a 9 5 cm x 20 cm silica column. The column was eluted with 20% to 35% ethyl acetate/hexane followed by 5% ethanol/chloroform, and finally by 5% ethanol/5% isopropylamine/chloroform. The fractions (eluted with the final solvent) which contained product (identified by GC-MS) were pooled 10 and concentrated in vacuo to yield 20.1 g of compound A.

Benzaldehyde (11 g, 0.104 moles) and compound A (20.1 g, 0.099 moles) were mixed together and swirled. After 20 minutes 20 mL of absolute ethanol were added and stirred for another 10 minutes followed by removal of the ethanol 15 and water in vacuo. The oil was taken up in 50 mL of dry ethanol to which sodium borohydride (3.74 g, 0.099 moles) was added. The reaction was stirred overnight at room temperature. The solvent was removed in vacuo, and the residue was taken up in ether and 50 mM sodium hydroxide. 20 The water layer was separated and the ether layer was washed 2 x with 50 mM sodium hydroxide, 1 x with brine, dried over sodium sulfate, and concentrated in vacuo to yield 28.8 g (99%) of compound B.

Compound B (28.8 g, 0.0985 moles) was dissolved in 25 400 mL of acetonitrile followed by addition of potassium fluoride/ Celite (22.9 g, 0.197 moles) and N-(3-bromo-propyl)phthalimide (39.61 g, 0.147 moles). The reaction was heated to reflux under argon for 10.5 hours. After cooling, the reaction was filtered and the solid washed 30 with acetonitrile. The combined acetonitrile solutions were concentrated in vacuo to yield a thick yellow oil. The oil was taken up in 1 L of ethanol to which 9.3 mL of hydrazine were added. The solution was heated to reflux under argon for 2.25 hours. The solvent was removed in 35 vacuo, and the residue was taken up in ether and 50 mM sodium hydroxide. The ether layer was separated, dried over sodium sulfate and stripped in vacuo to yield 33.4 g

WO 95/21612

PCT/US94/12293

91

of crude compound C. The crude material was chromatographed on a 9 cm x 30 cm silica column eluted with dichloromethane/methanol/isopropylamine (94:5:1) to give 26.9 g of compound C.

5 Benzaldehyde (8.54 g, 0.081 moles) and compound C (26.9 g, 0.0767 moles) were mixed together and swirled. After 30 minutes 20 mL of absolute ethanol were added and stirred for another 45 minutes followed by removal of the ethanol and water in vacuo. The oil was taken up in 80 mL
10 of dry ethanol to which sodium borohydride (2.9 g, 0.0767 moles) was added. The reaction was stirred overnight at room temperature. The solvent was removed in vacuo, and the residue was taken up in ether and 50 mM sodium hydroxide. The water layer was separated and the ether layer
15 was washed 2 x with 50 mM sodium hydroxide, 1 x with brine, dried over potassium carbonate, and concentrated in vacuo to yield 32.6 g (96%) of compound D.

Compound D (32.6 g, 0.0742 moles) was dissolved in 300 mL of acetonitrile followed by addition of potassium
20 fluoride/ Celite (17.24 g, 0.148 moles) and N-(3-bromo-propyl)phthalimide (29.83 g, 0.111 moles). The reaction was heated to reflux under argon for 15.25 hours. After cooling, the reaction was filtered and the solid washed with acetonitrile. The combined acetonitrile solutions
25 were stripped in vacuo. The oil was taken up in 750 mL of ethanol to which 7 mL of hydrazine were added. The solution was heated to reflux under argon for 2 hours. The solvent was removed in vacuo, and the residue was taken up in ether and 50 mM sodium hydroxide. The ether
30 layer was separated, dried over sodium sulfate and stripped in vacuo. The crude material was chromatographed on a 9 cm x 30 cm silica column eluted with dichloromethane/methanol/isopropylamine (94:5:1) to give 31.9 g of compound E.

35 Compound E (18.22 g, 36.7 mmoles) and tri-CBZ-arginine N-hydroxysuccinimde ester (25 g, 37.1 mmoles) were dissolved in 100 mL of dichloromethane and stirred

WO 95/21612

PCT/US94/12293

92

for 2 days at room temperature. The reaction mixture was diluted with chloroform and extracted with 50 mM sodium hydroxide. The organic layer was dried over sodium sulfate and the solvent removed in vacuo to give 40.4 g of 5 compound E. This material was used in the next step without further purification.

Compound E was dissolved in 400 mL of 50% trifluoroacetic acid/dichloromethane and stirred for 2 hours. The solvents were removed in vacuo, and the residue was taken 10 up in chloroform/100 mM sodium hydroxide. The chloroform layer was separated, dried over sodium sulfate, and stripped in vacuo. The crude compound G was used in the next step without purification.

All of compound G from step G, (approximately 36 15 mmoles) was dissolved in 175 mL of dichloromethane along with Boc-asparagine p-nitrophenyl ester (12.72 g, 36 mmoles). The reaction was stirred for 2 days at room temperature, then diluted up in chloroform and extracted 5 x with 50 mM sodium hydroxide, 1 x with brine, dried 20 over sodium sulfate and stripped in vacuo. The crude oil was chromatographed on a 9 cm x 30 cm silica column eluted with dichloromethane/methanol/isopropylamine (94:5:1) to give 29.3 g of compound H.

Compound H (7.29 g, 6.3 mmoles) was dissolved in 50 25 mL of 50% trifluoroacetic acid/dichloromethane and stirred under argon for 1 hour. The solvent was removed in vacuo and the residue dissolved in chloroform and 50 mM sodium hydroxide. The layers were separated and the water layer was extracted once more with chloroform. The combined 30 chloroform extracts were washed with brine, dried over potassium carbonate, and stripped in vacuo. The residual solid was dissolved in a small amount of chloroform and precipitated with ether. The solid was filtered off, washed with ether and dried under vacuum to give 5.61 g of 35 compound I.

Compound I (214 mg, 0.2 mmoles) was dissolved in 2 mL of chloroform. To this solution was added 2-methoxy-

WO 95/21612

PCT/US94/12293

93

phenylacetic acid N-hydroxysuccinimide ester (58 mg, 0.22 mmoles), and the solution was stirred overnight at room temperature. The reaction mixture was diluted with chloroform and washed with dilute sodium hydroxide. The 5 chloroform layer was separated, dried over sodium sulfate, and stripped *in vacuo* to give compound J which was used directly in the next step.

All of compound J from step J was dissolved in 5 mL of acetic acid. Palladium hydroxide on carbon (100 mg) 10 was added, and the reaction was put under hydrogen (from a hydrogen filled balloon) and stirred overnight. The reaction was filtered through a 0.2 micron syringe filter to remove the catalyst, and the resulting solution was lyophilized. The residue was dissolved in 0.1% trifluoro-15 acetic acid and chromatographed on a C-18 column (10 mm x 250 mm Vydac C-18) eluted with acetonitrile. The fraction containing product was lyophilized to give 90 mg of Compound 5 as the TFA salt.

The synthesis of Compound 6 was carried out in a 20 manner analogous to that for Compound 5 except that in step H, compound G was reacted with Boc-phenylalanine N-hydroxysuccinimide ester instead of Boc-asparagine p-nitrophenyl ester.

The synthesis of Compound 7 was carried out in a 25 manner analogous to that for Compound 5 except than in step H, compound G was reacted with Boc-leucine N-hydroxysuccinimide ester instead of Boc-asparagine p-nitrophenyl ester.

The synthesis of Compound 8 was carried out in a 30 manner analogous to that for Compound 5 except that in step F, compound E was reacted with CBZ-lysine N-hydroxysuccinimide ester instead of tri-CBZ-arginine N-hydroxysuccinimide ester.


The synthesis of Compound 10 was carried out in a 35 manner analogous to that for Compound 5 except that in step J, compound I was coupled to 2-benzyloxyphenylacetic

WO 95/21612

PCT/US94/12293

94


acid N-hydroxysuccinimide ester instead of 2-methoxyphenylacetic acid N-hydroxysuccinimide ester.



WO 95/21612

PCT/US94/12293

95



Synthesis of Compound 9 was accomplished as follows:

To a solution of 1,3-diaminopropane (100 g, 1.35 mol) in methanol (100 mL) was added acrylonitrile (79 g, 1.48 mol) dropwise over a 10 min period. The reaction was

WO 95/21612

PCT/US94/12293

96

stirred 4 hr at room temperature and concentrated to an oil. This material was distilled under reduced pressure and 66 g (39%) *N*-cyanoethyl-1,3-diaminopropane, A, was collected at a boiling range of 95-115° C.

5 To a solution of A (66 g, 520 mmol) in dichloromethane (1 L) was added di-*tert*-butyl dicarbonate (250 g, 1.14 mol). The reaction was stirred for 16 hr at room temperature. After this time the reaction was washed with 1.0 N NaOH (1x), dried with anhydrous potassium carbonate, 10 and concentrated to an oil. Chromatography (silica) using a gradient of hexane to ethyl acetate-hexane (1:1) afforded 73 g (43%) of the product B.

A solution of B (73 g, 222 mmol) and palladium dihydroxide (10 g, 20% Pd) in acetic acid (750 mL) was 15 hydrogenated under 55 p.s.i. hydrogen for 4 hr at room temperature. The reaction mixture was filtered and the catalyst washed with acetic acid (3 x 100 mL). The filtrate and acetic acid washes were combined and concentrated to a thick oil. This material was equilibrated 20 between dichloromethane (1 L) and 1 N NaOH (1 L). The organic layer was separated, dried over anhydrous K₂CO₃, and concentrated to afford 73.5 g (100%) of the product C.

A solution of C (69.6 g, 210 mmol) in methanol (300 mL) was treated dropwise over a 10 min period with 25 acrylonitrile (11.2 g, 211 mmol) and the reaction stirred 16 hr at room temperature. After this time the reaction was concentrated to an oil. A solution of this material in dichloromethane (300 mL) was treated with di-*tert*-butyl dicarbonate (46.1 g, 211 mmol) and the reaction stirred 16 30 hr at room temperature. After this time the reaction mixture was concentrated to an oil. Chromatography (silica) using a gradient of hexane to ethyl acetate-hexane (1:1) gave 79.5 g (77%) of the product D.

A solution of D (79.5 g, 162 mmol) and palladium 35 dihydroxide (4 g, 20% Pd) in acetic acid (800 mL) was hydrogenated at 55 p.s.i. hydrogen for 4 hr at room temperature. After this time the reaction mixture was

WO 95/21612

PCT/US94/12293

97

filtered and the catalyst washed with acetic acid (3 x 100 mL). The filtrate and the acetic acid washes were combined and concentrated to a thick oil. This material was equilibrated between dichloromethane (1 L) and 1 N NaOH (1 L). The organic layer was separated, dried over anhydrous potassium carbonate, and concentrated to afford 79 g (100%) of the product E.


A solution of E (1.4 g, 2.87 mmol), 5-fluoro-indole-3-acetic acid (507 mg, 2.62 mmol), and 1-trihydroxybenzotriazole (858 mg, 6.35 mol) were mixed in DMF (5 mL) and treated with DCC (594 mg, 2.88 mmol) in chloroform (5 mL). The reaction mixture was stirred 4 hr at room temperature after which it was filtered and concentrated. Chromatography (silica) using a gradient of dichloromethane to methanol-dichloromethane (1:9) afforded 1.1 g (58%) of the product F.

A solution of the amide F (1.1 g, 1.66 mmol) in acetonitrile (36 mL) was treated dropwise over a 1 min period with concentrated HCl (4 mL). The reaction was stirred 4 hr at room temperature. The acetonitrile was evaporated, *in vacuo*, and the crude product dissolved in water to a total volume of 10 mL. This material was chromatographed through Vyadac RP (C_{18} , 20 x 2.5 cm i.d.) in ten aliquots (1 mL) using a gradient (0.6%/min) of 0.1% HCl to acetonitrile at 10 mL/min measuring optical density at 280 nm to afford 483 mg (80%) of Compound 9. FABMS observed ($M^+ H$) $m/z = 364$.

WO 95/21612

PCT/US94/12293

98



Synthesis of Compound 11 was accomplished as follows:

A solution of ethylamine hydrochloride (100 g, 1.23 mol) in methanol (500 mL) was cooled to 0°C and treated 5 with triethylamine (130 g, 1.29 mol) followed by acrylonitrile (65.2 g, 1.23 mol). The reaction was then warmed to room temperature and stirred for 16 hr. To this was added di-tert-butyl dicarbonate (268 g, 1.23 mol) in dichloromethane (300 mL). The reaction was stirred 4 hr 10 at room temperature, concentrated and dissolved in diethyl ether. This was washed with 10% HCl (3x), 0.1 N NaOH (3x) and brine (1x). The ether fraction was dried over K_2CO_3 and concentrated to afford 220 g (91%) of the product A, as an oil. GC-MS ($R_t = 3.964$ min) m/z (relative intensity) 15 198 (M⁺, 2), 143 (7), 125 (27), 97 (31), 57 (100).

A solution of A (50 g, 253 mmol) and palladium dihydroxide (5 g) in acetic acid (300 mL) was hydrogenated at 70 p.s.i. hydrogen for 16 hr at room temperature. The

SUBSTITUTE SHEET (RULE 26)

WO 95/21612

PCT/US94/12293

99

reaction was filtered and the catalyst washed with acetic acid (3x). The filtrate and acetic acid washes were combined and concentrated to a thick oil. This material was dissolved in dichloromethane (500 mL) and treated with 5 1 N NaOH until the pH of the equilibrated phases was basic (pH 14). The organic layer was removed, dried over K_2CO_3 and concentrated to afford, 39.06 g (76%) of the product B, as an oil.

10 A solution of B (39.06 g, 193.4 mmol) in methanol (50 mL) was treated with benzaldehyde (20.5 g, 193.4 mmol) and anhydrous $MgSO_4$. The reaction was stirred 8 hr at room temperature and poured directly into a solution of sodium borohydride (7.3 g, 193 mmol) in ethanol (300 mL). The reaction was stirred 4 hr at room temperature, quenched 15 with dilute HCl and concentrated in vacuo. The acidic solution was basified with 1 N NaOH and the product extracted into ether. The ether layer was dried and concentrated to afford 19.5 g (35%) of the product C as an oil.

20 A solution of C (19.5 g, 66.8 mmol) in acetonitrile (100 mL) was treated with *N*-(3-bromopropyl)phthalimide (19.7 g, 73 mmol), KF-Celite (8.5 g, 50% KF) and set to reflux for 16 hr. The reaction was then filtered and concentrated to afford intermediate D. A solution of 25 this material in methanol (500 mL) was treated with hydrazine (15 mL) and refluxed for 4 hr. After this time the reaction was concentrated to a white solid and dissolved in ether-1 N NaOH. The aqueous layer was removed and the remaining ether washed with 1 N NaOH (3x), brine, 30 and concentrated to an oil. Chromatography (silica) using a gradient of chloroform to chloroform-methanol (9:1) afforded 6.47 g (28%) of the product E as a clear oil.

35 A solution of E (6.47g, 18.5 mmol) in methanol (50 mL) was treated with benzaldehyde (2.06 g, 19.5 mmol) and anhydrous $MgSO_4$ and stirred 8 hr at room temperature. After this the reaction was poured directly into a solution of sodium borohydride (1 g, 26 mmol) in ethanol (300

WO 95/21612

PCT/US94/12293

100

mL) and stirred for 4 hr at room temperature. The reaction was quenched with dilute HCl and concentrated. This material was suspended in ether and treated with 1 N NaOH until pH 14. The ether layer was separated, dried over 5 K_2CO_3 and concentrated to afford the intermediate F (6.23 g) as an oil. A solution of this material in acetonitrile (50 mL) was treated with *N*-(3-bromopropyl)phthalimide (5.4 g, 20 mmol), KF-Celite (2.3 g) and set to reflux for 16 hr. The reaction was filtered and concentrated. This 10 material, containing intermediate G, in methanol (300 mL) was treated with hydrazine (10 mL) and refluxed for 4 hr. After this time the reaction was concentrated to a white solid and dissolved in ether-1 N NaOH. The aqueous layer was removed and the remaining ether washed with 1 N NaOH 15 (3x), brine, and concentrated to an oil. Chromatography (silica) through silica using a gradient of chloroform to chloroform-methanol (9:1) afforded 4.5 g (49%) of the product H as a clear oil.

A solution of 5-fluoro-3-indole acetic acid (2 g, 20 10.4 mmol) and *p*-nitrophenol (1.6 g, 11.6 mmol) in chloroform-DMF (100:1, 200 mL) was treated with DCC (2.18 g, 10.6 mmol) and the reaction stirred at 16 hr at room temperature. The reaction mixture containing the active ester I was filtered directly into a stirred solution of 25 H (4.5g g, 9 mmol). This reaction was stirred 4 hr at room temperature and poured into 300 mL ether. The ether layer was washed with 1 N NaOH (6x), brine, dried, and concentrated to an oily solid. This material was chromatographed through a small silica plug using 30 chloroform-methanol to afford the intermediate J. A solution of this material, and a catalytic amount of palladium dihydroxide in acetic acid (200 mL) was hydrogenated under 60 p.s.i. hydrogen for 2 hr at room temperature. The reaction was filtered and the catalyst 35 washed with acetic acid (3x). The filtrate and washes were combined and concentrated to afford K as a thick oil. A solution of this material in acetonitrile (20 mL) was

WO 95/21612

PCT/US94/12293


101

treated with concentrated HCl (2 mL) and the reaction stirred under nitrogen for 2 hr at room temperature. The reaction was filtered and the precipitate (crude Compound 11) dissolved in 5 mL H₂O. The concentration of product 5 was determined as 233 mM by UV. Analytic RP HPLC showed the product to be 91% pure. Chromatography of a portion of this material (in 100 uL aliquots) through Vydac RP (C₁₈, 25 x 2 cm) using a gradient (1%/min) of 0.1% HCl to acetonitrile, at 10 mL/min monitoring optical density at 10 280 nm, gave pure Compound 11. UV_{max} (0.1% TFA) 284 nm (e 6140).

WO 95/21612

PCT/US94/12293

102



Synthesis of Compound 12 was accomplished as follows:

A solution of 4,9-dioxa-1,12-dodecanediamine (50 g, 245 mmol) in dioxane (500 mL) was treated dropwise over 60 min with a solution of di-*tert*-butyl dicarbonate (5.88 g, 27 mmol) in dioxane (300 mL). The reaction was stirred 24 hr at room temperature and reduced to a white solid. This material was partitioned between water-hexane. GC-MS of the organic and aqueous fractions showed di-addition product in the hexane fraction with the product A and starting diamine in the aqueous fraction. The aqueous

WO 95/21612

PCT/US94/12293

103

layer was separated and washed with ether. GC-MS analysis showed the product A in the ether layer and starting diamine in the aqueous layer. The ether layer was separated, dried over sodium sulfate and concentrated to afford 5 10.2 g (14%) of the product A, as a clear oil. GC-EIMS (R_t = 8.86 min), m/z (relative intensity) 205 (M^+ 1, 5), 148 (59), 130 (16), 114 (17), 100 (16), 74 (61), 58 (100).


A solution of 5-fluoro-indole-3-acetic acid (2 g, 10.4 mmol) and *p*-nitrophenol (1.73 g, 12.4 mmol) in 10 chloroform-DMF (75:1, 125 mL) was treated with DCC (2.25 g, 10.9 mmol) and the reaction stirred 24 hr at room temperature. This was then filtered (removing DCU) directly into a stirred solution of A (5.2 g, 17.1 mmol) in chloroform (100 mL). After this addition triethylamine 15 was added (2g, 20 mmol) and the reaction stirred 4 hr at room temperature. The solution was added to ether (600 mL) and washed with 1N NaOH (6 x 100 mL), 10% HCl (1 x 100 mL) and brine. The organic layer was dried (sodium sulfate) and concentrated to a clear oil. Chromatography 20 (silica) using chloroform-methanol (50:1) afforded 4.93 g (99% from the indole) of the product B, as a clear oil.

A solution of compound B (4.93 g, 10.3 mmol) in acetonitrile (50 mL) was treated with concentrated HCl (5 mL) and the solution stirred 4 hr at room temperature. 25 Evaporation of the solvent *in vacuo*, and lyophilization from water afforded (5.26 g, 99%) of Compound 12, as a thick oil. 1H -NMR ($CDCl_3$, free base) δ 9.92 (1H, br s), 7.30 (1H, dd, $J=9$ Hz, $J=4$ Hz), 7.20 (1H, dd, $J=9$ Hz, $J=2$ Hz), 7.19 (1H, s), 6.94 (1H, dt, $J=9$ Hz, $J=2$), 6.30 (1H br t), 3.67 (2H, s), 3.56 (2H, t, $J=6$ Hz), 3.40 (2H, t, $J=6$ Hz), 3.32 (4H, br t, $J=6$ Hz), 3.10 (2H, t, $J=7$ Hz), 2.88 (2H, t, $J=7$ Hz), 1.79 (2H, p, $J=6$ Hz), 1.72 (2H, br m), 1.64 (2H, p, $J=6$ Hz), 1.44 (2H, m), 1.36 (2H, m); ^{13}C -NMR ($CDCl_3$, free base) δ 171.2, 125.7, 112.1, 112.0, 110.8, 35 110.4, 104.4, 103.8, 103.5, 71.0, 70.9, 70.0, 69.4, 39.9, 38.5, 33.4, 32.9, 28.8, 26.5, 26.4.

WO 95/21612

PCT/US94/12293

104



Compounds 13 - 18 were synthesized by standard procedures as described above.

Example 29: Synthesis of simplified arylalkyl-amines

Synthesis of Compound 20 was accomplished as follows:

- 5 A solution of sodium hydride (1.21 g, 50 mmol) in dimethoxyethane was treated with diethyl cyanomethylphosphonate (8.86 g, 50 mmol) and the reaction stirred 4 hr at room temperature. To this was added 3,3'-difluorobenzophenone (10 g, 46 mmol) in DME. The reaction was stirred
10 24 hr at room temperature, quenched with H₂O, and partitioned between diethyl ether and water. The ether fraction was dried over Na₂SO₄ and concentrated. GC-MS of this material showed 90% of the product A and 10% starting benzophenone.
- 15 A solution of this material in ethanol with a catalytic amount of Pd(OH)₂ was hydrogenated at 55 p.s.i. hydrogen for 4 hr at room temperature. The reaction was filtered and the catalyst washed with ethanol (3x). The filtrate and ethanol washes were combined and concentrated. GC-MS of this material showed 90% of the product B and 10% of the starting benzophenone.

20 A solution of this material in THF was treated with 70 mL 1 M B₂H₆ (70 mmol) in THF and refluxed 1 hr. After cooling the reaction was treated with 6 N HCl (50 mL) and
25 refluxed an additional hour. After cooling the reaction was basified to pH 14 with 10 N NaOH and equilibrated with ether. The ether layer was removed and washed with 10%

WO 95/21612





PCT/US94/12293

105

HCl (3x). The acidic washes were combined, basified to pH 14 with 10 N NaOH and extracted with dichloromethane (3x). The organic washes were combined, dried over Na_2SO_4 , and concentrated to yield an oil. GC-MS of this material showed 100% Compound 20. GC-EIMS ($R_t = 7.11$ min) m/z (relative intensity) 247 (M^+ , 31), 230 (100), 215 (30), 201 (52), 183 (63), 134 (23), 121 (16), 101 (21), 95 (15), 77 (15). This material in diethyl ether was filtered and treated with 35 mL 1 M HCl in ether. The precipitate was collected, dried, and recrystallized from water-ethanol to afford 1.045 g of Compound 20, as the hydrochloride salt. $^1\text{H-NMR}$ (CDCl_3) d 8.28 (3H, br s), 7.28-7.17 (2H, m), 7.02-6.86 (6H, m), 4.11 (1H, t, $J=8$ Hz), 2.89 (2H, br t, $J=8$ Hz), 2.48 (2H, br t, $J=7$ Hz); $^{13}\text{C-NMR}$ (CDCl_3) d 164.6, 161.3, 144.8, 144.7, 130.4, 130.3, 123.3, 123.2, 114.7, 114.5, 114.1, 113.8, 47.4, 38.4, 32.7.


1) NaH-DME

2)


3) H_2O  $\text{Pd}(\text{OH})_2\text{-EtOH}$ H_2 55 p.s.i.

A

B

 1) $\text{B}_2\text{H}_6\text{-THF}$
 2) 6 N HCl
 3) NaOH (pH 14)


Compound 20



Synthesis of Compound 21, Compound 33 and Compound 34 was accomplished as follows:

WO 95/21612

PCT/US94/12293

106

A 100 ml round-bottomed flask equipped with stir bar, septa, and argon source was charged with compound **1** (2.43 g, 10 mmol) in 30 mL THF. The solution was cooled to -78 °C and treated dropwise with 11 mL 1M (THF) lithium bis-
5 (trimethylsilyl)amide (11 mmol). The reaction was stirred at -78 °C for 30 min and treated dropwise with excess iodomethane (50 mmol, 3.1 mL). The reaction was stirred 30 min at -58 °C. GC-EI-MS analysis of an aliquot from the reaction showed consumption of the starting nitrile **1**
10 . The reaction was quenched with water, diluted with diethyl ether and transferred to a separatory funnel. The ether layer was washed with 10% HCl (3X), brine (1X), dried with anhydrous MgSO₄, and concentrated to a brown oil. This material was distilled (Kugelrohr, 100 °C) at
15 reduced pressure to afford 1.5 g of a clear oil. GC-EI-MS of this material showed it to contain the desired product **2**, (*R_t*=7.35 min) m/z (rel. int.) 257 (M⁺, 3), 203 (100), 183 (59), 170 (5), 133 (4), 109 (3); ¹H-NMR (CDCl₃) 7.4-
6.9 (8H, m), 4.01 (1H, d, J=10 Hz), 3.38 (1H, dq, J=7, 10
20 Hz), 1.32 (3H, d, J=7 Hz); ¹³C-NMR (CDCl₃) 19.4, 30.5,
54.2, 114.5, 114.6, 114.7, 114.9, 115.0, 115.3, 123.3,
123.4, 123.6, 123.7, 130.5, 130.6, 131.7.

Product **3** was synthesized by the catalytic reduction of **2** using Raney nickel in 95:5 EtOH:aqueous sodium hydroxide (2 Eq.) under 60 p.s.i. hydrogen. GC-EI-MS (*R_t*=7.25 min) m/z (rel. int.) 261 (M⁺, 20), 244 (35), 229 (16), 215 (17), 201 (80), 183 (100), 133 (42), 115 (27), 109 (47), 95 (20); ¹H-NMR (CDCl₃) 7.3-6.8 (8H, m), 3.62 (1H, d, J=10 Hz), 2.70 (1H, M), 2.40 (2H, m), 1.73 (2H, m), 0.91 (3H, d, J=7 Hz). Note that product **3** in this reaction sequence corresponds to Compound 21.

Product **2** in 10% IPA-hexane (100 mg/mL) was chromatographed, in 500 uL aliquots, through Chiral Cel OD (2.0 x 25 cm) using 10% IPA-hexane at 10 ml/min measuring optical density at 254 nm. This afforded the two optically pure enantiomers **4** and **5** (as determined by analytical chiral HPLC; Note, the stereochemistry of these

WO 95/21612

PCT/US94/12293

107



two compounds has not been assigned at this time). These two compounds were identical in their GC-EI-MS and ¹H-NMR spectra as product 2 (data above).

Each of the enantiomers 4 and 5 were reduced 5 separately using dimethyl sulfide-borane complex in the following manner. A solution of compound (4 or 5) in THF was heated to reflux and treated with excess (2 Eq.) 1M (in THF) dimethyl sulfide-borane complex and the reaction refluxed 30 min. After this time the reaction 10 was cooled to 0 °C and treated with 6 N HCl. The reaction was set to reflux for 30 min. After this time the reaction was transferred to a separatory funnel, basified to pH > 12 with 10N NaOH, and the product (6 or 7) extracted into ether. The ether layer was washed with 15 brine, dried over anhydrous MgSO₄ and concentrated to an oil. The product was purified by Prep-TLC using 5% methanol-chlorform. Each of the individual enantiomers (6 and 7) were found to be identical in their GC-EI-MS and ¹H-NMR spectra as product 3 (data above). Note that 20 products 6 and 7 in this scheme correspond to Compounds 33 and 34.

WO 95/21612

PCT/US94/12293

108



Synthesis of Compound 22 was accomplished as described below. Compound 23 was synthesized in a similar manner.

Triethyl phosphonoacetate (17.2 g, 76.8 mmol) was slowly added to a suspension of sodium hydride (3.07 g, 76.8 mmol) in 350 mL of N,N-dimethyl formamide. After 15 minutes 3,3'-difluorobenzophenone (15.2 g, 69.8 mmol) was added to the solution and stirred an additional 18 hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give 19.7 g of ethyl 3,3-bis(3-fluorophenyl)acrylate as a yellow oil.

WO 95/21612

PCT/US94/12293

109

To a solution of ethyl 3,3-bis(3-fluorophenyl)-acrylate (19.7 g, 68.4 mmol) in 200 mL of ethanol was added palladium hydroxide on carbon (3.5 g). The mixture was shaken under 60 psi of hydrogen for 3 hours, then 5 filtered and evaporated *in vacuo* to give 19.5 g of product A as a colorless oil.

The ethyl ester A (19.2 g) was hydrolyzed by stirring for 6 days with 50 mL of 10 N sodium hydroxide. The reaction mixture was then diluted with 50 mL of water and 10 acidified to pH 0 with concentrated HCl. The aqueous mixture was extracted 3 times with ether and the ether extracts dried over magnesium sulfate and evaporated to give 3,3-bis(3-fluorophenyl)propionic acid as a white powder.

15 3,3-bis(3-fluorophenyl)propionic acid (13 g, 49.6 mmol) was dissolved in 50 mL (685 mmol) of thionyl chloride and stirred overnight at room temperature. The excess thionyl chloride was removed *in vacuo* on a rotary evaporator to give 13.7 g of product B as a yellow oil.

20 To acid chloride B (13.7 g, 49 mmol) dissolved in 100 mL of dry THF was added iron(III) acetylacetone (0.52 g, 1.47 mmol). Methyl magnesium chloride (16.3 mL, 49 mmol) was then added over a period of 1 hour by syringe pump. The reaction was stirred for an additional hour, then 25 quenched by dumping into ether/5% HCl. The ether layer was separated and washed with 5% HCl and saturated NaCl and dried over sodium sulfate. The solvent was evaporated *in vacuo* to give 4,4-bis(3-fluorophenyl)-2-butanone as a yellow oil. The crude oil was purified on silica gel 30 using heptane/ethyl acetate as the elutant.

To 4,4-bis(3-fluorophenyl)-2-butanone (5.7 g, 21.9 mmol) in 25 mL of ethanol was added pyridine (1.91 g, 24.1 mmol) and methoxylamine hydrochloride (2.01 g, 24.1 mmol). The reaction was stirred overnight at room temperature, 35 then poured into ether/5% HCl. The ether layer was separated, washed with 5% HCl and saturated NaCl, and dried over sodium sulfate. The solvent was evaporated in

WO 95/21612

PCT/US94/12293

110




vacuo to give 6.26 g of the O-methyl oxime of 4,4-bis(3-fluorophenyl)-2-butanone.

To sodium borohydride (4.1 g, 108.3 mmol) in 15 mL of THF was slowly added zirconium tetrachloride (6.31 g, 27.1 mmol). This mixture was stirred for 15 min, then the oxime (6.26 g, 21.7 mmol) in 6 mL of THF was added over 5 min. After 3 hours of stirring at room temperature, the reaction was worked up by slowly adding 50 mM sodium hydroxide followed by ether. The aqueous layer was extracted 4 times with ether, and the combined ether extracts were dried over sodium sulfate. The solvent was evaporated in vacuo to give 5.3 g of Compound 22.

WO 95/21612

PCT/US94/12293

111



Compound 22

Synthesis of Compound 24 was accomplished as described below. Compounds 25-29 were prepared in a similar manner.

A suspension of magnesium turnings (0.95 g, 39.2 mmol) in 150 ml anhydrous diethyl ether was treated with 1-bromo-3-fluorobenzene (6.83 g, 39.2 mmol) dropwise via syringe. After 1.5 hr the solution was transferred via

WO 95/21612

PCT/US94/12293

112

cannula to a flask containing o-anisaldehyde (5.0 g, 36.7 mmol) in 100 ml anhydrous diethyl ether at 0°C and stirred 2hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic 5 layers were washed with brine and dried over anhydrous magnesium sulfate to afford 7.90g (93% yield) of product A.

Pyridinium dichromate (16.0 g, 42.5 mmol) was added to a solution of the alcohol A (7.90 g, 34.0 mmol) in 100 10 ml dichloromethane and the reaction stirred 12hr. Diethyl ether, 300 ml, was added to the reaction mixture and the black solution was filtered through a silica gel plug, 30 cm, and washed with an additional 500 ml ether. After evaporation of the solvent *in vacuo*, the solid was 15 recrystallized from acetone to give 7.45 g (95% yield) of product B.

Diethyl cyanomethylphosphonate (7.0 g, 39.5 mmol) was slowly added to a suspension of sodium hydride (1.58 g, 39.5 mmol) in 100 ml N,N-dimethyl formamide. After 30 20 minutes the ketone B was added to the solution and stirred an additional 2 hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was 25 evaporated *in vacuo* to give a pale yellow oil.


In a glass bomb, the oil was dissolved in 100 ml ethanol and 20 ml 10N NaOH. A catalytic amount of Raney Nickel suspened in water (ca. 15 mol percent) was added to the solution. The reaction mixture was shaken under 60 30 p.s.i. H₂ for 12 hr on a Parr Hydrogenator. After filtering off excess Raney Nickel, the solution was extracted with chloroform. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. After filtration, the oil was run through a silica gel 35 column in chloroform and methanol. The solvent was evaporated *in vacuo* to give a pale yellow oil. GC-EIMS (R_t=8.10 min) m/z (rel. intensity) 259 (100), 242 (44), 213

WO 95/21612

PCT/US94/12293

113

(48), 183 (42), 136 (50), 109 (94), 91 (60), 77 (25). The oil was then acidified with hydrogen chloride in diethyl ether. Evaporation of the ether afforded a pale yellow solid that was recrystallized in hot acetonitrile to afford 3.45 g (42.1% yield) white needles of Compound 24.



Compound 24

Synthesis of Compound 30 was accomplished as described below. Compound 31 was prepared in a similar manner.

A suspension containing magnesium turnings (0.95 g, 10 39.1 mmol) in 150 ml anhydrous diethyl ether was treated with 1-bromo-3-fluorobenzene (6.85 g, 39.1 mmol) dropwise via syringe. After 1.5 hr the solution was transferred via cannula to a flask containing 3-chlorobenzaldehyde (5.0 g, 35.6 mmol) in 100 ml anhydrous diethyl ether at 0°C and 15 stirred 2 hr. The reaction mixture was quenched with water and partitioned between water and ether. The

WO 95/21612

PCT/US94/12293

114

combined organic layers were washed with brine and dried over anhydrous magnesium sulfate to afford 8.40g (>99% yield) of product A.

Pyridinium chlorochromate (15.0 g, 39.8 mmol) was 5 added to a solution of the alcohol A (8.40 g, 35.5 mmol) in 100 ml dichloromethane and stirred 18hr. Diethyl ether, 300 ml, was added to the reaction mixture and the black solution was filtered through a silica gel plug, 30 cm, and washed with an additional 500 ml ether. After 10 evaporation of the solvent the solid was recrystallized from acetone to give 6.31 g (76% yield) of product B.

Diethyl cyanomethylphosphonate (5.2 g, 29.6 mmol) was slowly added to a suspension of sodium hydride (1.2 g, 29.6 mmol) in 100 ml N,N-dimethyl formamide. After 30 15 minutes the ketone B was added to the solution and stirred an additional 6 hr. The reaction mixture was quenched with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was 20 evaporated in vacuo to give a yellow oil.


In a glass bomb, the oil was dissolved in 100 ml ethanol and 20 ml 10N NaOH. A catalytic amount of rhodium suspended on alumina (ca. 35 mol percent) was added to the solution. The reaction mixture was shaken under 60 p.s.i. 25 H₂ for 24 hr on a Parr Hydrogenator. After filtering off excess rhodium, the solution was extracted with chloroform. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. After filtration and evaporation of the solvent in vacuo, the oil was 30 taken up in 100 ml tetrahydrofuran. Diborane (23.4 ml, 1.0M) was added and the solution refluxed for 1.5 hr. The solvent was evaporated in vacuo and 50 ml 6N HCl added carefully. The solution was refluxed for 1 hr. After cooling, the mixture was basified with 10N NaOH to pH 14 35 and partitioned between dichloromethane and water. The combined organic layers were dried over anhydrous magnesium sulfate and filtered. After evaporation of the

WO 95/21612

PCT/US94/12293

115

solvent, the yellow oil was run through a silica gel column in chloroform and methanol. The solvent was evaporated in vacuo to give a yellow oil. GC-EIMS (R_t =8.15 min) m/z (rel. intensity) 263 (17), 246 (21), 211 (84),
5 196 (33), 183 (100), 165 (19), 133 (19). The oil was then acidified with hydrogen chloride in diethyl ether. Evaporation of the ether afforded 0.96 g of a white solid, Compound 30.



Synthesis of Compound 35 was accomplished as
10 described below. Compounds 36-37 were prepared in a similar manner.

A solution of 3-fluorobenzaldehyde (3.0 g, 24.2 mmol) at 0°C in 150 ml diethyl ether was treated with 3.0M ethyl magnesium chloride (12.7 ml, 25.4 mmol) in tetrahydofuran via syringe. After 4 hr the reaction mixture was quenched

WO 95/21612

PCT/US94/12293

116

with water and partitioned between water and ether. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate to afford 4.25 g of product A.

5 Pyridinium chlorochromate (6.53 g, 30.3 mmol) was added to a solution of A in 100 ml dichloromethane and stirred 18 hr. Diethyl ether, 300 ml, was added to the reaction mixture and the black solution was filtered through a silica gel plug, 30 cm, and washed with an
10 additional 500 ml ether. After evaporation of the solvent the solid was recrystallized from acetone to give 3.05 g of product B. The solvent was evaporated *in vacuo* to give a pale yellow oil.

Diethyl cyanomethylphosphonate (4.7 g, 26.4 mmol) was
15 slowly added to a suspension of sodium hydride (1.1 g, 26.4 mmol) in 100 ml N,N-dimethyl formamide. After 30 minutes the ketone B was added to the solution and stirred an additional 6 hr. The reaction mixture was quenched with water and partitioned between water and ether. The
20 combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated *in vacuo* to give a yellow oil.


In a glass bomb, the oil was dissolved in 100 ml ethanol and 20 ml 10N NaOH. A catalytic amount of Raney
25 Nickel suspened in water (ca. 15 mol percent) was added to the solution. The reaction mixture was shaken under 60 p.s.i. H₂ for 24 hr on a Parr Hydrogenator. After filtering off excess Raney Nickel, the solution was extracted with chloroform. The combined organic layers were washed
30 with brine and dried over anhydrous magnesium sulfate. After filtration, the oil was run through a silica gel column in chloroform and methanol. The solvent was evaporated *in vacuo* to give a pale yellow oil. GC-EIMS (R_t=3.45 min) m/z (rel. intensity) 167 (4), 150 (63), 135
35 (58), 109 (100), 96 (53), 75 (48). The oil was then acidified with hydrogen chloride in diethyl ether. Evaporation of the ether left a pale yellow solid that was

WO 95/21612

PCT/US94/12293

117

recrystallized in hot acetonitrile to afford 2.2 g of Compound 35.



Synthesis of Compound 38 was accomplished as described below.

- 5 To a solution of 3,3-bis(3-fluorophenyl)propionitrile (1.5 g, 6.17 mmol) in 250 mL of THF at -70°C was added butyl lithium (4.25 mL in hexanes, 6.8 mmol) by syringe over 5 minutes. The solution was stirred for 5 min then methyl iodide (1.75 g, 12.3 mmol) was added over 1 min.
- 10 The reaction mixture was then allowed to warm up to room temperature. Worked up by diluting with ether and washing with 5% HCl and water. The ether layer was dried over sodium sulfate and evaporated to give 1.5 g of the methylated nitrile as a yellow oil.
- 15 To the 3,3-bis(3-fluorophenyl)-2-methylpropionitrile (1.46 g, 5.7 mmol) in 50 mL of dichloromethane at 0°C was added diisobutylaluminum hydride (1.02 mL, 5.7 mmol) by syringe over a 10 min period. The reaction was stirred

WO 95/21612

PCT/US94/12293

118

for 30 min at 0°C followed by 2 additional hours at room temperature. The reaction was worked up by adding 200 mL of 10% HCl and stirring at 40°C for 30 min followed by extraction of the product with dichloromethane. The 5 organic layer was dried over sodium sulfate and evaporated to give 1.36 g of the product A.

To a solution of the aldehyde A (1.36 g, 5.23 mmol) in 40 mL of ether at 0°C was added methylmagnesium bromide (5.23 mL in ether, 5.23 mmol). The reaction was stirred 10 for 3 hours at room temperature, and then quenched with dilute HCl. The ether layer was separated, dried over sodium sulfate and evaporated to give 1.48 g of 4,4-bis(3-fluorophenyl)-3-methylbutan-2-ol.

To a solution of the alcohol (1.4 g, 5.07 mmol) in 15 300 mL of dichloromethane was added pyridinium chlorochromate (1.2 g, 5.58 mmol), and the mixture was stirred overnight. The reaction was then diluted with 100 mL of ether and filtered through a silica plug. The solvents were evaporated to give 1.39 g of product B.

20 The ketone B (1.3 g, 4.9 mmol) was added to a solution of methoxylamine hydrochloride (0.45 g, 5.38 mmol) and pyridine (0.44 mL, 5.38 mmol) in 30 mL of ethanol, and stirred overnight. The ethanol was then evaporated, and the residue taken up in ether and 10% HCl. 25 The ether layer was separated, washed once with 10% HCl, dried over sodium sulfate and evaporated to give 1.4 g of the O-methyl oxime.


To a suspension of sodium borohydride (0.87 g, 23.1 mmol) in 5 mL of THF was added zirconium tetrachloride 30 (1.35 g, 5.8 mmol), and the solution was stirred for 15 min followed by the addition of another 5 mL of THF. The O-methyl oxime (1.4 g, 4.6 mmol) in 5 mL of THF was then added, and the mixture stirred overnight. The THF was removed by evaporation in vacuo, and the residue treated 35 with 10% sodium hydroxide. After the bubbling ceased ether was added and the layers separated. The aqueous layer was extracted 4 times with ether, and the combined

WO 95/21612

PCT/US94/12293

119

ether extracts were dried over sodium sulfate. The ether was evaporated to give 1.25 g of Compound 38.



WO 95/21612

PCT/US94/12293

120

Compound 32 and Compounds 39 - 53 were synthesized according to standard procedures as described above.

Example 30: Biological properties of synthesized arylalkylamines

5 Compounds synthesized as described in Example 28 and Example 29 were tested for various biological properties detailed in the examples.

Table 1

	Compound	IC ₅₀ (μ M) vs. NMDA ^a	IC ₅₀ (μ M) vs. [³ H]MK-801 ^c
10	Compound 1	0.102 (7)	126 (4)
	Compound 2	0.192 (4)	not tested
	Compound 3	0.003 (7)	not tested
	Compound 4	0.184 (5)	89 (1)
	Compound 5	0.102 (1) 0.070 (3) ^b	15.2 (2)
15	Compound 6	0.129 (1)	> 100 (1) (0% at 100 μ M) ^d
	Compound 7	0.163 (2)	129 (1)
	Compound 8	0.099 (2)	219 (1)
	Compound 9	1.2 (5)	> 100 (2) (10% at 100 μ M) ^d
20	Compound 10	0.082 (2)	~ 80 (1) (57% at 80 μ M) ^d
	Compound 11	4.0 (2)	not tested
	Compound 12	6.0 (11)	98 (1)
	Compound 13	not tested	not tested
	Compound 14	8.8 (2)	~ 100 μ M
25	Compound 15	4.9 (3)	~ 100 μ M
	Compound 16	5.1 (1)	28.8 (1)
	Compound 17	9.6 (1)	36.3 (1)
	Compound 18	5.1 (3)	34 (1)
	Compound 19	0.407 (7)	2.4 (3)
	Compound 20	0.058 (6)	0.426 (3)

WO 95/21612

PCT/US94/12293

121

	Compound	IC ₅₀ (μ M) vs. NMDA ^a	IC ₅₀ (μ M) vs. [³ H]MK-801 ^c
5	Compound 21	0.029 (2) 0.038 (5) ^e 0.468 (3) ^e	0.602 (1) 0.380 (1) ^e 4.1 (1) ^e
	Compound 22	0.136 (4)	1.2 (1)
	Compound 23	0.267 (3)	5.4 (1)
	Compound 24	0.190 (1)	0.724 (1)
	Compound 25	0.245 (1)	1.4 (1)
	Compound 26	42 (1)	34 (1)
	Compound 27	0.071 (1)	0.275 (1)
	Compound 28	0.380 (1)	2.7 (1)
	Compound 29	1.9 (2)	6.2 (1)
	Compound 30	0.208 (2)	1.6 (1)
10	Compound 31	0.039 (4)	1.7 (1)
	Compound 32	not tested	not tested
	Compound 33	not tested	not tested
	Compound 34	not tested	not tested
	Compound 35	6.2 (1)	25.1 (1)
	Compound 36	not tested	not tested
15	Compound 37	0.944 (2)	3.8 (1)
	Compound 38	0.468 (1)	2.8 (1)
	Compound 39	not tested	not tested
	Compound 40	not tested	not tested
	Compound 41	0.724 (1)	12.6 (1)
20	Compound 42	not tested	not tested
	Compound 43	not tested	not tested
	Compound 44	not tested	not tested
	Compound 45	not tested	not tested
25	Compound 46	not tested	not tested
	Compound 47	not tested	not tested
	Compound 48	not tested	not tested
	Compound 49	not tested	not tested
	Compound 50	not tested	not tested
30	Compound 51	not tested	not tested

WO 95/21612

PCT/US94/12293

122

Compound	IC ₅₀ (μ M) vs. NMDA ^a	IC ₅₀ (μ M) vs. [³ H]MK-801 ^c
Compound 52	not tested	not tested
Compound 53	not tested	not tested

^a: Inhibition of NMDA/glycine-induced increases in intracellular calcium in cultured rat cerebellar granule cells (RCGC's) (see Example 1). (# in parenthesis indicates the number of experiments)

^b: TFA salt

^c: Inhibition of ³[H]MK-801 binding in rat cortical/hippocampal washed membrane preparations (see Example 4).

^d: IC₅₀ study incomplete. % inhibition at the stated concentration.

^e: diastereomers of Compound 21 (Compounds 33 and 34) whose stereochemistry has not been assigned at this time

A comparison of the IC₅₀ values in the RCGC assay with the IC₅₀ values in the [³H]MK-801 binding assay illustrates that the arylalkylamines of the invention inhibit NMDA receptor activity by a mechanism different than that of binding to the MK-801 binding site; the concentration of the compound that inhibits NMDA receptor function is several orders of magnitude less than the concentration that competes at the site labeled by [³H]MK-801. This is not the case, however, with the simplified arylalkylamines exemplified by Compounds 19 - 53. Such compounds bind to the site labeled by [³H]MK-801 at concentrations ranging approximately 1 to 50-fold higher than those which antagonize NMDA receptor-mediated function in the rat cerebellar granule cell assay.

WO 95/21612

PCT/US94/12293

123

Table 2

Compound	Suppression of NMDA Receptor-Mediated Synaptic Transmission ^a	LTP Assay ^b	Drop in Mean Arterial Blood Pressure ^c
Compound 1	10 - 30 μ M	no block at 300 μ M	65 mm Hg at 1.5 μ moles/kg i.v., 60 min duration
Compound 2	10 - 30 μ M	no block at 100 μ M	40 mm Hg at 1.5 μ moles/kg i.v., 120 min duration
5 Compound 3	10 - 30 μ M	not tested	20 mm Hg at 1 mg/kg s.c., > 60 min duration
Compound 4	10 - 100 μ M	no block at 100 μ M	40 mm Hg at 1.5 μ moles/kg i.v., 120 min duration
Compound 9	10 - 100 μ M	no block at 300 μ M	75 mm Hg at 4.5 μ moles/kg i.v., 90 min duration
Compound 11	not tested	not tested	20 mm Hg at 1 mg/kg i.v., 30 min duration
10 Compound 12	not tested	not tested	no effect at doses up to 37.3 μ moles/kg i.v.
Compound 14	not tested	not tested	no effect at doses up to 15 μ moles/kg i.v.

WO 95/21612

PCT/US94/12293

124

Compound	Suppression of NMDA Receptor-Mediated Synaptic Transmission ^a	LTP Assay ^b	Drop in Mean Arterial Blood Pressure ^c
Compound 19	100 - 300 μ M	block at 100 μ M	not tested
Compound 20	30 - 300 μ M	block at 100 μ M	no effect at doses up to 15 μ moles/kg i.v.
Compound 22	not tested	not tested	no effect at doses up to 15 μ moles/kg i.v.

^a:Concentration which suppresses NMDA receptor-mediated synaptic transmission (see Example 5).

^b:Concentration that does not block the induction of LTP (see Example 19).

^c:Drop in systemic blood pressure produced by administration of compound in rats (see Example 22).

Advantageous properties of the arylalkylamine compounds of the present invention are illustrated by the fact that concentrations which suppress NMDA receptor-mediated synaptic transmission fail to inhibit LTP. Furthermore, while compounds such as Compound 9, and 11 do produce a hypotensive response following systemic administration in rats, the hypotensive effect produced by these compounds is of a relatively short duration (approximately 30 min). Additionally, Compounds 12 and 14 have no cardiovascular activity at doses up to 37.3 μ moles/kg i.v. and 15 μ moles/kg i.v., respectively.

Formulation and Administration

As demonstrated herein, useful compounds of this invention and their pharmaceutically acceptable salts may

WO 95/21612

PCT/US94/12293

125

be used to treat neurological disorders or diseases. While these compounds will typically be used in therapy for human patients, they may also be used to treat similar or identical diseases in other vertebrates such as other 5 primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.

In therapeutic and/or diagnostic applications, the compounds of the invention can be formulated for a variety of modes of administration, including systemic and topical 10 or localized administration. Techniques and formulations generally may be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton PA.

The exact formulation, route of administration and dosage can be chosen by the individual physician in view 15 of the patient's condition. (See e.g. Fingl et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1).

It should be noted that the attending physician would know how and when to terminate, interrupt, or adjust 20 administration due to toxicity or organ dysfunction. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical responses were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the 25 oncogenic disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose 30 frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.

Depending on the specific conditions being treated, 35 such agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in *Remington's Pharmaceutical*

WO 95/21612

PCT/US94/12293

126

Sciences, Mack Publishing Co., Easton PA. Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intra-medullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intra-nasal, or intraocular injections, just to name a few.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal

WO 95/21612

PCT/US94/12293

127

contents are both protected from the external micro-environment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, 5 small organic molecules may be directly administered intracellularly.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to 10 achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in 20 the form of tablets, dragees, capsules, or solutions.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, 25 encapsulating, entrapping or lyophilizing processes.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspension. Suitable lipophilic 30 solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid ester, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the 35 viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents

WO 95/21612

PCT/US94/12293

128

which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid 5 excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or 10 sorbitol; cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents 15 may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be 20 used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or pigments may be added to the tablets or dragee coatings 25 for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, 30 such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may 35 be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol's. In addition, stabilizers may be added.

SUBSTITUTE SHEET (RULE 26)

WO 95/21612**PCT/US94/12293****129**

Other embodiments are within the following claims.

WO 95/21612

PCT/US94/12293

130

Claims

1. Method for screening for a therapeutically useful compound, active on a receptor-operated calcium channel as a noncompetitive antagonist, comprising the 5 step of:

identifying a compound which binds to said receptor-operated calcium channel at a site bound by one of the arylalkylamines Compound 1, Compound 2 and Compound 3.

2. The method of claim 1 where said receptor-operated calcium channel is part of an NMDA receptor-ionophore complex. 10

3. The method of claim 1 where said receptor-operated calcium channel is part of a calcium-permeable AMPA receptor-ionophore complex.

15 4. The method of claim 1 where said receptor-operated calcium channel is part of a nicotinic cholinergic receptor-ionophore complex.

5. The method of claim 1 where said compound is useful for the therapeutic treatment of a neurological disorder or neurodegenerative disease. 20

6. The method of claim 1 where said compound has therapeutic utility as an anticonvulsant, neuroprotectant, anxiolytic, analgesic, muscle relaxant or adjunct in general anesthesia.

25 7. Method for treating a patient having a neurological disease or disorder, comprising the step of administering a pharmaceutical composition comprising a compound which binds to a receptor-operated calcium channel at the site bound by one of the arylalkylamines 30 Compound 1, Compound 2 and Compound 3, said compound being a potent and selective noncompetitive antagonist at such


WO 95/21612

PCT/US94/12293

131

a receptor-operated calcium channel, and having one or more of the following pharmacological and physiological properties: efficacy in *in vitro* biochemical and electro-physiological assays of receptor-operated calcium channel function, *in vivo* anticonvulsant activity, *in vivo* neuro-protectant activity, *in vivo* anxiolytic activity, and *in vivo* analgesic activity; said compound also possessing one or more of the following pharmacological effects: the compound does not interfere with the induction of long-term potentiation in rat hippocampal slices, and, at a therapeutic dose, does not impair cognition, does not disrupt motor performance, does not produce neuronal vacuolization, has minimal cardiovascular activity, does not produce sedation or hyperexcitability, is devoid of PCP-like abuse potential, and is devoid of PCP-like psychotomimetic activity.

8. Method of claim 7 for treating a patient having a neurological disease or disorder comprising administering a pharmaceutical composition comprising a polyamine-type compound or an analog thereof having the formula:



wherein Ar is an appropriately substituted aromatic ring, ring system or other hydrophobic entity; Ar can be an aromatic, heteroaromatic, alicyclic (cycloaliphatic), or heteroalicyclic ring or ring system (mono-, bi-, or tricyclic), having 5- to 7-membered ring(s) optionally substituted with 1 to 5 substituents independently selected from lower alkyl of 1 to 5 carbon atoms, lower haloalkyl of 1 to 5 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 5 carbon atoms, halogen, nitro, amino, lower alkylamino of 1 to 5 carbon atoms, amido, lower alkylamido of 1 to 5 carbon atoms,

WO 95/21612

PCT/US94/12293

132

cyano, hydroxyl, sulfhydryl, lower acyl of 2 to 4 carbon atoms, sulfonamido, lower alkylsulfonamido of 1 to 5 carbon atoms, lower alkylsulfoxide of 1 to 5 carbon atoms, lower hydroxyalkyl of 1 to 5 carbon atoms, lower alkylketo of 1 to 5 carbon atoms, or lower thioalkyl of 1 to 5 carbon atoms,

each m is an integer from 0 to 3, inclusive,
each k is an integer from 1 to 10, inclusive,
each j is the same or different and is an integer
10 from 1 to 12, inclusive,

each R¹ and R² are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 5 carbon atoms, lower alkylamino of 1 to 5 carbon atoms, lower alkylamido of 1 to 5 carbon atoms, lower mono-, di-, or
15 trifluoroalkyl of 1 to 5 carbon atoms, hydroxy, amidino, guanidino, or typical common amino acid side chain or with an associated carbon atom R¹ and R² taken together form a carbonyl, and

each Z is selected from the group consisting of
20 nitrogen, oxygen, sulfur, amido, sulfonamido, and carbon.

9. Method of claim 8 wherein Ar comprises a moiety selected from the group consisting of Headgroup A, Headgroup B, Headgroup C, Headgroup D, Headgroup E, Headgroup F, and Headgroup G.


25 10. Method for treating a patient having a neurological disease or disorder comprising administering a pharmaceutical composition comprising a compound selected from the group consisting of Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound
30 7, Compound 8, Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14, Compound 15, Compound 16, Compound 17 or Compound 18, or a pharmaceutically acceptable salt thereof.

WO 95/21612

PCT/US94/12293

133

11. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof, having the formula:



wherein Ar is an appropriately substituted aromatic ring, ring system or other hydrophobic entity; Ar can be an aromatic, heteroaromatic, alicyclic (cycloaliphatic), or heteroalicyclic ring or ring system (mono-, bi-, or tricyclic), having 5- to 7-membered ring(s) optionally substituted with 1 to 5 substituents independently selected from lower alkyl of 1 to 5 carbon atoms, lower haloalkyl of 1 to 5 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 5 carbon atoms, halogen, nitro, amino, lower alkylamino of 1 to 5 carbon atoms, amido, lower alkylamido of 1 to 5 carbon atoms, cyano, hydroxyl, sulfhydryl, lower acyl of 2 to 4 carbon atoms, sulfonamido, lower alkylsulfonamido of 1 to 5 carbon atoms, lower alkylsulfoxide of 1 to 5 carbon atoms, lower hydroxyalkyl of 1 to 5 carbon atoms, lower alkylketo of 1 to 5 carbon atoms, or lower thioalkyl of 1 to 5 carbon atoms,

each m is an integer from 0 to 3, inclusive,

25 each k is an integer from 1 to 10, inclusive,

each j is the same or different and is an integer from 1 to 12, inclusive,

each R¹ and R² are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 5 carbon atoms, lower alkylamino of 1 to 5 carbon atoms, lower alkylamido of 1 to 5 carbon atoms, lower mono-, di-, or trifluoroalkyl of 1 to 5 carbon atoms, hydroxy, amidino, guanidino, or typical common amino acid side chain or with an associated carbon atom R¹ and R² taken together form a carbonyl, and

WO 95/21612

PCT/US94/12293

134

each Z is selected from the group consisting of nitrogen, oxygen, sulfur, amido, sulfonamido, and carbon, wherein said compound being a potent and selective non-competitive antagonist at such a receptor-operated calcium channel, and having one or more of the following pharmacological and physiological properties: efficacy in *in vitro* biochemical and electrophysiological assays of receptor-operated calcium channel function, *in vivo* anticonvulsant activity, *in vivo* neuroprotectant activity, *in vivo* anxiolytic activity, and *in vivo* analgesic activity; said compound also possesses one or more of the following pharmacological effects: the compound does not interfere with the induction of long-term potentiation in rat hippocampal slices, and, at a therapeutic dose, does not impair cognition, does not disrupt motor performance, does not produce neuronal vacuolization, has minimal cardiovascular activity, does not produce sedation or hyperexcitability, is devoid of PCP-like abuse potential, and is devoid of PCP-like psychotomimetic activity; in a pharmaceutically acceptable carrier and dose.

12. A composition selected from the group consisting of Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14, Compound 15, Compound 16, Compound 17 or Compound 18, or a pharmaceutically acceptable salt thereof.


13. The composition of claim 12 in a pharmaceutically acceptable carrier and dose.

14. Method for treating a patient having a neurological disease or disorder comprising administering a pharmaceutical composition comprising one of the following structures:


WO 95/21612

PCT/US94/12293


135




where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH_3 , and each R^1 can be, independently, H, lower alkyl, OH, O-alkyl or O-acyl, and each R^2 can be, independently, H or lower alkyl; or



5 where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH_3 , and each R^1 can be, independently, H, lower alkyl, OH, O-alkyl, or O-acyl, and each R^2 can be, independently, H or lower alkyl; or



where n = 1-6, and each X can be, independently, one or
10 more H, Br, Cl, F, lower alkyl, and/or OCH_3 , and R^1 can be H, lower alkyl, OH, O-alkyl, or O-acyl, and R^2 can be H or lower alkyl; or



WO 95/21612

PCT/US94/12293


136

where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl.


- 5 15. Method for treating a patient having a neurological disease or disorder comprising administering a pharmaceutical composition comprising Compound 19, Compound 20, Compound 21, Compound 22, Compound 23, Compound 24, Compound 25, Compound 26, Compound 27, 10 Compound 28, Compound 29, Compound 30, Compound 31, Compound 32, Compound 33, Compound 34, Compound 35, Compound 36, Compound 37, Compound 38, Compound 39, Compound 40, Compound 41, Compound 42, Compound 43, Compound 44, Compound 45, Compound 46, Compound 47, 15 Compound 48, Compound 49, Compound 50, Compound 51, Compound 52 or Compound 53, or a pharmaceutically acceptable salt thereof.

16. A composition having the following structure, except Compound 19,

20



where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl or O-acyl, and each R² can be, independently, H or lower alkyl; or




SUBSTITUTE SHEET (RULE 26)

WO 95/21612


PCT/US94/12293

137

where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl; or




- 5 where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and R² can be H or lower alkyl; or



- 10 where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl; or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition having the
15 structure:



where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, indepen-


SUBSTITUTE SHEET (RULE 26)

WO 95/21612


PCT/US94/12293

138


dently, H, lower alkyl, OH, O-alkyl or O-acyl, and each R² can be, independently, H or lower alkyl; or



where each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and each R¹ can be, independently, H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl; or



where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and R² can be H or lower alkyl; or



where n = 1-6, and each X can be, independently, one or more H, Br, Cl, F, lower alkyl, and/or OCH₃, and R¹ can be H, lower alkyl, OH, O-alkyl, or O-acyl, and each R² can be, independently, H or lower alkyl; in a pharmaceutically acceptable carrier and dose.

18. A composition of claim 16 consisting of Compound 19, Compound 20, Compound 21, Compound 22, Compound 23,

WO 95/21612

PCT/US94/12293

139

- Compound 24, Compound 25, Compound 26, Compound 27,
Compound 28, Compound 29, Compound 30, Compound 31,
Compound 32, Compound 33, Compound 34, Compound 35,
Compound 36, Compound 37, Compound 38, Compound 39,
5 Compound 40, Compound 41, Compound 42, Compound 43,
Compound 44, Compound 45, Compound 46, Compound 47,
Compound 48, Compound 49, Compound 50, Compound 51,
Compound 52 or Compound 53, or a pharmaceutically acceptable salt thereof.
- 10 19. A pharmaceutical composition of claim 17 comprising Compound 19, Compound 20, Compound 21, Compound 22, Compound 23, Compound 24, Compound 25, Compound 26, Compound 27, Compound 28, Compound 29, Compound 30, Compound 31, Compound 32, Compound 33, Compound 34,
15 Compound 35, Compound 36, Compound 37, Compound 38, Compound 39, Compound 40, Compound 41, Compound 42, Compound 43, Compound 44, Compound 45, Compound 46, Compound 47, Compound 48, Compound 49, Compound 50, Compound 51, Compound 52 or Compound 53.